var title_f33_0_33792="Melioidosis ulcer";
var content_f33_0_33792=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F80092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F80092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Skin ulcer in melioidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 259px; height: 394px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Solitary skin ulcer as a cutaneous manifestation of melioidosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bart Currie, FRACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_0_33792=[""].join("\n");
var outline_f33_0_33792=null;
var title_f33_0_33793="Patient information: Ringworm, athleteâ€™s foot, and jock itch (The Basics)";
var content_f33_0_33793=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15478\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/12/37071\">",
"         Acute tinea pedis",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?3/19/3377\">",
"         Patient information: Ringworm (including athlete's foot and jock itch) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Ringworm, athlete&rsquo;s foot, and jock itch (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/ringworm-athletes-foot-and-jock-itch-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H481983482\">",
"      <span class=\"h1\">",
"       What are ringworm, athlete&rsquo;s foot, and jock itch?",
"      </span>",
"      &nbsp;&mdash;&nbsp;They are skin infections caused by a fungus. These types of fungal infections are also called &ldquo;tinea.&rdquo;",
"     </p>",
"     <p>",
"      Doctors and nurses call these fungal infections &ldquo;ringworm,&rdquo; because they often cause a ring-shaped, red, itchy rash on the skin. But a ring-shaped rash is not always there. People with athlete&rsquo;s foot may instead have moist, raw skin between their toes, or flaking skin on the bottoms of their feet (",
"      <a class=\"graphic graphic_picture graphicRef63389 \" href=\"mobipreview.htm?36/12/37071\">",
"       picture 1",
"      </a>",
"      ). People with jock itch often just have a red rash on the groin.",
"     </p>",
"     <p>",
"      Sometimes, especially in children, the fungus can infect the scalp. On the scalp, the infection looks like a round flaky patch of skin.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H481983489\">",
"      <span class=\"h1\">",
"       How did I get a fungal infection?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can catch fungal infections from anyone who is infected. You can also catch them from an infected dog or cat. Plus, you can pick up the infections from places where the fungus might be, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A shower stall",
"       </li>",
"       <li>",
"        The locker room floor",
"       </li>",
"       <li>",
"        The area near a pool",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you have a fungal infection on one part of your body, you can also spread it to other parts. For instance, men with a fungal infection on their feet sometimes spread it to their groin.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H481983496\">",
"      <span class=\"h1\">",
"       How are fungal infections treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The treatment for a fungal infection depends on which body part is affected. If you have a fungal infection on your scalp, you must take pills that will kill the fungus. Treatment with these pills usually lasts 1 to 3 months.",
"     </p>",
"     <p>",
"      If you have a fungal infection on your feet, groin, or another body part, you probably will not need pills. Instead, you can use a gel, cream, lotion, or powder that you put on the skin. Treatment with these products lasts 2 to 4 weeks.",
"     </p>",
"     <p>",
"      If you have a fungal infection on your groin and on your feet, you must treat both infections at the same time. If you do not, the infection on your feet can spread to your groin again.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H481983503\">",
"      <span class=\"h1\">",
"       How do I keep from getting a fungal infection again?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If someone in your home has had a fungal infection on their scalp:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Get rid of any combs, brushes, barrettes, or other hair products that could have the fungus on them",
"       </li>",
"       <li>",
"        Make sure a doctor or nurse checks everyone in the house for a fungal infection",
"       </li>",
"       <li>",
"        If the fungal infection may have come from a pet, have it checked by a vet",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Here are some other general tips on how to prevent fungal infections:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Do not share unwashed clothes, sports gear, or towels with other people",
"       </li>",
"       <li>",
"        Always wear slippers or sandals when at the gym, pool, or other public areas. That includes public showers.",
"       </li>",
"       <li>",
"        Wash with soap and shampoo after sports or exercise",
"       </li>",
"       <li>",
"        Change your socks and underwear at least once a day",
"       </li>",
"       <li>",
"        Keep your skin clean and dry. Always dry yourself well after swimming or showering.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H481983510\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/19/3377?source=see_link\">",
"       Patient information: Ringworm (including athlete's foot and jock itch) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?33/0/33793?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15478 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-202.43.93.2-77D3A94D3A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_0_33793=[""].join("\n");
var outline_f33_0_33793=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H481983482\">",
"      What are ringworm, athlete&rsquo;s foot, and jock itch?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H481983489\">",
"      How did I get a fungal infection?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H481983496\">",
"      How are fungal infections treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H481983503\">",
"      How do I keep from getting a fungal infection again?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H481983510\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15478\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/12/37071\">",
"      Acute tinea pedis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/19/3377?source=related_link\">",
"      Patient information: Ringworm (including athlete's foot and jock itch) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_0_33794="CT scan jejunal adenoCA";
var content_f33_0_33794=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F73944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F73944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Axial image of a contrast-enhanced CT scan demonstrates a proximal adenocarcinoma of the jejunum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 341px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Michael Overman.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_0_33794=[""].join("\n");
var outline_f33_0_33794=null;
var title_f33_0_33795="Zinc chloride: Patient drug information";
var content_f33_0_33795=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Zinc chloride: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/25/32146?source=see_link\">",
"     see \"Zinc chloride: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/50/29475?source=see_link\">",
"     see \"Zinc chloride: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help growth and good health.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703146",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to zinc chloride or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into a vein for a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12156 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-704953041C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_0_33795=[""].join("\n");
var outline_f33_0_33795=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013361\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013360\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013364\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013365\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013367\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013363\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013368\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013369\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?31/25/32146?source=related_link\">",
"      Zinc chloride: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/50/29475?source=related_link\">",
"      Zinc chloride: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_0_33796="Calculator: CIWA-Ar Clinical Institute Withdrawal Assessment for Alcohol scale";
var content_f33_0_33796=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"CIWA_form\" name=\"CIWA_form\" onreset=\"rrclr();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: CIWA-Ar Clinical Institute Withdrawal Assessment for Alcohol scale",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_main\">",
"     <div id=\"calc_input\">",
"      <center>",
"       <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           NAUSEA AND VOMITING: Ask \"Do you feel sick to your stomach? Have you vomited?\" Observation.",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           No nausea and no vomiting (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Mild nausea with no vomiting (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Intermittent nausea with dry heaves (4 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Constant nausea, frequent dry heaves, and vomiting (7 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           TREMOR: Arms extended and fingers spread apart. Observation.",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           No tremor (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Not visible, but can be felt fingertip to fingertip (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Moderate, with patient's arms extended (4 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Severe, even with arms not extended (7 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           PAROXYSMAL SWEATS: Observation.",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           No sweat visible (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Barely perceptible sweating, palms moist (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Beads of sweat obvious on forehead (4 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Drenching sweats (7 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           ANXIETY: Ask \"Do you feel nervous?\" Observation.",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           No anxiety, at ease (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Mildly anxious (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Moderately anxious, or guarded, so anxiety is inferred (4 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Equivalent to acute panic states as seen in severe delirium or acute schizophrenic reactions (7 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           AGITATION: Observation.",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Normal activity (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Somewhat more than normal activity (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Moderately fidgety and restless (4 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Paces back and forth during most of the interview, or constantly thrashes about (7 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           TACTILE DISTURBANCES: Ask \"Have you any itching, pins and needles sensations, burning sensations, numbness or do you feel bugs crawling on or under your skin?\" Observation.",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc6\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           None (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc6\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Very mild itching, pins and needles, burning or numbness (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc6\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Mild itching, pins and needles, burning or numbness (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc6\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Moderate itching, pins and needles, burning or numbness (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc6\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Moderately severe hallucinations (4 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc6\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Severe hallucinations (5 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc6\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Extremely severe hallucinations (6 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc6\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Continuous hallucinations (7 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           AUDITORY DISTURBANCES: Ask \"Are you more aware of sounds around you? Are they harsh? Do they frighten you? Are you hearing anything that is disturbing to you? Are you hearing things you know are not there?\" Observation.",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc7\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Not present (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc7\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Very mild harshness or ability to frighten (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc7\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Mild harshness or ability to frighten (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc7\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Moderate harshness or ability to frighten (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc7\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Moderately severe hallucinations (4 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc7\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Severe hallucinations (5 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc7\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Extremely severe hallucinations (6 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc7\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Continuous hallucinations (7 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           VISUAL DISTURBANCES: Ask \"Does the light appear to be too bright? Is its color different? Does it hurt your eyes? Are you seeing anything that is disturbing to you? Are you seeing things you know are not there?\" Observation.",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc8\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Not present (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc8\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Very mild sensitivity (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc8\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Mild sensitivity (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc8\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Moderate sensitivity (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc8\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Moderately severe hallucinations (4 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc8\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Severe hallucinations (5 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc8\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Extremely severe hallucinations (6 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc8\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Continuous hallucinations (7 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           HEADACHE, FULLNESS IN HEAD: Ask \"Does your head feel different? Does it feel as if there is a band around your head?\" Do not rate for dizziness or lightheadedness. Otherwise, rate severity.",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc9\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Not present (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc9\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Very mild (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc9\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Mild (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc9\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Moderate (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc9\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Moderately severe (4 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc9\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Severe (5 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc9\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Very severe (6 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc9\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Extremely severe (7 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           ORIENTATION AND CLOUDING OF SENSORIUM: Ask \"What day is this? Where are you? Who am I?\" Count forward by three.",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc10\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Oriented and can do serial additions (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc10\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Cannot do serial additions or is uncertain about date (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc10\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Disoriented for date by no more than two calendar days (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc10\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Disoriented for date by more than two calendar days (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc10\" onclick=\"CIWA_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Disoriented for place and/or person (4 points)",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <div id=\"calc_result\">",
"      <span class=\"medCalcFontCCTabBold\">",
"       Total Criteria Point Count:",
"      </span>",
"      <input name=\"cctotal\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <input name=\"reset\" type=\"reset\" value=\"Reset Form\"/>",
"      </center>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"       <tr>",
"        <td bgcolor=\"#eeeeee\" width=\"1%\">",
"         <br/>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <span class=\"medCalcFontTitleBox\">",
"          CIWA Score Interpretation",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"        <tr id=\"rr1_1\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           0 to 9 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           Very mild withdrawal",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_2\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           10 to 15 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           Mild withdrawal",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_3\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           16 to 20 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           Modest withdrawal",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_4\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           21 to 67 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           Severe withdrawal",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"     </span>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Stuppaeck CH, Barnas C, et al. Assessment of the alcohol withdrawal syndrome - validity and reliability of the translated and modified Clinical Institute Withdrawal Assessment for Alcohol scale (CIWA-A).",
"        <i>",
"         Addiction",
"        </i>",
"        . 1994; 89:1287-1292.",
"       </span>",
"      </li>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Sullivan JT, Sykora K, et al. Assessment of alcohol withdrawal: The revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar).",
"        <i>",
"         Br J Addiction",
"        </i>",
"        . 1989; 89:1353-1357.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"   <script language=\"JavaScript1.1\" type=\"text/javascript\">",
"    &lt;!--",
"",
";",
"CIWA_fx();",
"//--&gt;",
"   </script>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_0_33796=[" ",
"",
"var calctxt = '';",
"var xmltxt = '';",
"var htmtxt = '';",
"",
"",
"function CIWA_fx() {",
"with(document.CIWA_form){",
"",
"Score = 0.0;",
"doCalc = true;",
"",
"if (cc1[0].checked){",
"Score = Score + 0;",
"}",
"if (cc1[1].checked){",
"Score = Score + 1;",
"}",
"if (cc1[2].checked){",
"Score = Score + 4;",
"}",
"if (cc1[3].checked){",
"Score = Score + 7;",
"}",
"if (cc2[0].checked){",
"Score = Score + 0;",
"}",
"if (cc2[1].checked){",
"Score = Score + 1;",
"}",
"if (cc2[2].checked){",
"Score = Score + 4;",
"}",
"if (cc2[3].checked){",
"Score = Score + 7;",
"}",
"if (cc3[0].checked){",
"Score = Score + 0;",
"}",
"if (cc3[1].checked){",
"Score = Score + 1;",
"}",
"if (cc3[2].checked){",
"Score = Score + 4;",
"}",
"if (cc3[3].checked){",
"Score = Score + 7;",
"}",
"if (cc4[0].checked){",
"Score = Score + 0;",
"}",
"if (cc4[1].checked){",
"Score = Score + 1;",
"}",
"if (cc4[2].checked){",
"Score = Score + 4;",
"}",
"if (cc4[3].checked){",
"Score = Score + 7;",
"}",
"if (cc5[0].checked){",
"Score = Score + 0;",
"}",
"if (cc5[1].checked){",
"Score = Score + 1;",
"}",
"if (cc5[2].checked){",
"Score = Score + 4;",
"}",
"if (cc5[3].checked){",
"Score = Score + 7;",
"}",
"if (cc6[0].checked){",
"Score = Score + 0;",
"}",
"if (cc6[1].checked){",
"Score = Score + 1;",
"}",
"if (cc6[2].checked){",
"Score = Score + 2;",
"}",
"if (cc6[3].checked){",
"Score = Score + 3;",
"}",
"if (cc6[4].checked){",
"Score = Score + 4;",
"}",
"if (cc6[5].checked){",
"Score = Score + 5;",
"}",
"if (cc6[6].checked){",
"Score = Score + 6;",
"}",
"if (cc6[7].checked){",
"Score = Score + 7;",
"}",
"if (cc7[0].checked){",
"Score = Score + 0;",
"}",
"if (cc7[1].checked){",
"Score = Score + 1;",
"}",
"if (cc7[2].checked){",
"Score = Score + 2;",
"}",
"if (cc7[3].checked){",
"Score = Score + 3;",
"}",
"if (cc7[4].checked){",
"Score = Score + 4;",
"}",
"if (cc7[5].checked){",
"Score = Score + 5;",
"}",
"if (cc7[6].checked){",
"Score = Score + 6;",
"}",
"if (cc7[7].checked){",
"Score = Score + 7;",
"}",
"if (cc8[0].checked){",
"Score = Score + 0;",
"}",
"if (cc8[1].checked){",
"Score = Score + 1;",
"}",
"if (cc8[2].checked){",
"Score = Score + 2;",
"}",
"if (cc8[3].checked){",
"Score = Score + 3;",
"}",
"if (cc8[4].checked){",
"Score = Score + 4;",
"}",
"if (cc8[5].checked){",
"Score = Score + 5;",
"}",
"if (cc8[6].checked){",
"Score = Score + 6;",
"}",
"if (cc8[7].checked){",
"Score = Score + 7;",
"}",
"if (cc9[0].checked){",
"Score = Score + 0;",
"}",
"if (cc9[1].checked){",
"Score = Score + 1;",
"}",
"if (cc9[2].checked){",
"Score = Score + 2;",
"}",
"if (cc9[3].checked){",
"Score = Score + 3;",
"}",
"if (cc9[4].checked){",
"Score = Score + 4;",
"}",
"if (cc9[5].checked){",
"Score = Score + 5;",
"}",
"if (cc9[6].checked){",
"Score = Score + 6;",
"}",
"if (cc9[7].checked){",
"Score = Score + 7;",
"}",
"if (cc10[0].checked){",
"Score = Score + 0;",
"}",
"if (cc10[1].checked){",
"Score = Score + 1;",
"}",
"if (cc10[2].checked){",
"Score = Score + 2;",
"}",
"if (cc10[3].checked){",
"Score = Score + 3;",
"}",
"if (cc10[4].checked){",
"Score = Score + 4;",
"}",
"cctotal.value = Score;",
"",
"if (doCalc){",
"rrclr();",
"if ((Score >= 0) && (Score <= 9)){ document.getElementById('rr1_1').bgColor = '#cccccc';",
"}",
"if ((Score >= 10) && (Score <= 15)){ document.getElementById('rr1_2').bgColor = '#cccccc';",
"}",
"if ((Score >= 16) && (Score <= 20)){ document.getElementById('rr1_3').bgColor = '#cccccc';",
"}",
"if ((Score >= 21) && (Score <= 67)){ document.getElementById('rr1_4').bgColor = '#cccccc';",
"}",
"",
"}",
"}",
"}",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"document.getElementById('rr1_3').bgColor = \"\";",
"document.getElementById('rr1_4').bgColor = \"\";",
"}",
"",
"",
""].join("\n");
var outline_f33_0_33796=null;
var title_f33_0_33797="Abdominal aortic aneurysm repair PI";
var content_f33_0_33797=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F57520&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F57520&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Abdominal aortic aneurysm repair",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 705px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    For open surgery repair, the doctor cuts open your belly and replaces the bulging part of the aorta with a tube called a \"graft.\" This tube is made from manmade materials. It is sewn into place. Blood can flow normally through it.",
"    <br>",
"     To repair the aorta with an endovascular stent graft, the doctor cuts into a blood vessel in your thigh (at the spot where your thigh meets the rest of your body) and inserts a folded graft. Then the doctor threads the graft up to the bulging part of the aorta and unfolds it. This type of graft is not sewn into place. Blood flows through the graft.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_0_33797=[""].join("\n");
var outline_f33_0_33797=null;
var title_f33_0_33798="Auxiliary services in pediatrics";
var content_f33_0_33798=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Auxiliary services in pediatrics",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/0/33798/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/0/33798/contributors\">",
"     Chantal Lau, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/0/33798/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/0/33798/contributors\">",
"     Teresa K Duryea, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/0/33798/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/0/33798/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/0/33798/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hospitals and communities have come to realize that providing medical care alone is not always sufficient for the well-being of the chronically ill. Recovery may be accelerated by the involvement of a variety of support services once the urgent medical needs have been addressed and the patient is stabilized. The function of several such hospital-based services that complement each other in accelerating the healing process of the young patient are described here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H199252312\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three main categories of auxiliary services for hospitalized children:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physical and occupational therapy are important to children whose physical development is not yet mature.",
"     </li>",
"     <li>",
"      Play and art therapy are means to safeguard healthy psychosocial development during a time of illness.",
"     </li>",
"     <li>",
"      Social services provided by social workers and chaplains help patients and families cope with the stress of illness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The need for these services varies for individual children depending upon the severity or length of their illness, their developmental stage, and their family environment. Thus, a team approach may best help to prioritize the service(s) that will be most beneficial to the children and their families.",
"   </p>",
"   <p>",
"    Young patients, even more so than adults, should not be isolated during care. The potential for growth and development in the early years is most dependent upon the presence of caring adults and a challenging and stimulating environment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33798/abstract/1\">",
"     1",
"    </a>",
"    ]. Anxiety and stress related to illness, separation, hospitalization, and medical encounters often interfere with a child's optimal response to medical treatment. For this reason, caretakers ought to aim to provide continued caring and warm human interactions to facilitate psychosocial adaptation, as well as to reduce fear and anxiety.",
"   </p>",
"   <p>",
"    The maintenance of a daily routine that is as normal as possible during recovery from an illness helps to sustain a challenging and stimulating environment. In addition, it offers the opportunity to practice the necessary physical and occupational activities that are important for the continued development of neuromotor skills. The attempt to maintain normalcy will improve the child's quality of life, which by itself may accelerate recovery.",
"   </p>",
"   <p>",
"    Auxiliary services have a common goal: to facilitate recovery and restore as normal a life as possible by minimizing the negative impact of prolonged illness or disability. An interactive association exists between these various support services and the medical team (",
"    <a class=\"graphic graphic_figure graphicRef53193 \" href=\"mobipreview.htm?24/27/25011\">",
"     figure 1",
"    </a>",
"    ). Knowledge of the child's health, functional, social, psychosocial, and spiritual limitations helps to identify the type of assistance from which the child will benefit most. In addition, because these services use different approaches, they offer young patients the advantage of choosing which approach best meets their needs.",
"   </p>",
"   <p>",
"    Although the various support services are gaining exposure and acceptance, the benefits they provide are not widely recognized because of a lack of scientifically conducted studies. Professionals in the field of physical and occupational therapy are beginning to recognize the importance of evidence-based practice in contrast to empirical experience. They are encouraging decisions to be made on sound clinical practice rather than on intuition or descriptive evidence. But the training in these methods is still lacking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33798/abstract/2\">",
"     2",
"    </a>",
"    ]. The benefits of play and art therapy are even more empirical. However, their increasing acceptance may be due to the recreational aspects they offer children and adolescents. Research in this domain is much needed because the effects of psychosocial elements in the healing process are not well understood. Nevertheless, the lack of evidence has not hindered the eagerness of patients and their families to turn to these alternative approaches to help them cope with sickness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THERAPEUTIC SERVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical and occupational therapists work with the whole child rather than with a particular physiologic system (eg, respiratory) or function (eg, speech). Their primary goals are first to facilitate",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    adaptation to the newly acquired physical limitations and then, through therapy, rehabilitate the patient. The approach to care differs based upon age-related patient needs. Because children are not miniature adults, their treatment should not be based upon experiences acquired from adult patients. The choice and administration of therapies must be appropriate for the physical and psychological developmental stage of the child. Compliance with therapy is optimized and efficacy increased if the therapy is well accepted by the recipient.",
"   </p>",
"   <p>",
"    A challenge for both physical and occupational therapists arises when a child has conflicting age-appropriate",
"    <span class=\"nowrap\">",
"     motor/occupational",
"    </span>",
"    and cognitive skills. While maintaining an awareness of the patient's limitation(s), the therapist needs to devise a treatment aimed at meeting both skill levels. Professionals also design treatment plans that include active participation of family members whenever feasible, depending upon familial circumstances and the intricacies of the necessary therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33798/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. However, as parents become involved in providing therapy, it is important that they focus on small gains, so as to maintain interest and hope in the care of their child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33798/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As mentioned above, a child's potential for growth and development is dependent upon a",
"    <span class=\"nowrap\">",
"     challenging/stimulating",
"    </span>",
"    environment, as well as the presence of caring adults. Animal and human studies have shown developmental retardation in the young when isolated from physical contact [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33798/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. The importance of such contact has been recognized by Eastern cultures for centuries in their routine provision of massage therapy to infants and children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33798/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Physical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary concern of a physical therapist is to optimize the motor development of children whose activities have been restricted by their illness. Neuromotor maturation occurs from birth through adolescence; even during illness, appropriate stimulation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    activity are necessary if normal development is to take place.",
"   </p>",
"   <p>",
"    A physical therapist must have knowledge of the norms for neuromotor and cognitive milestones to make a correct diagnosis and offer a suitable treatment plan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33798/abstract/2\">",
"     2",
"    </a>",
"    ]. The therapist must select age-appropriate skills as functional outcomes if the therapy is to be efficacious.",
"    <span class=\"nowrap\">",
"     He/she",
"    </span>",
"    also must consider the child's cognitive and perceptual abilities in order to offer an intervention that will be stimulating and motivational.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For infants whose mobility is limited or hospital stay is prolonged, such as those born prematurely, physical therapists focus on positioning to minimize deformities and facilitate normal neuromuscular development.",
"     </li>",
"     <li>",
"      For young children, physical therapists teach proper play positioning (eg, tailor positioning (cross-legged) or inside sitting (with both legs bent on the same side) instead of W-sitting) to avoid contracture and potential deformation of the hips.",
"     </li>",
"     <li>",
"      For adolescents, physical therapists focus on independent mobility.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Occupational therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;People, being occupational in nature, organize themselves around a rhythmic temporal pattern: a balance of work, rest, play, and sleep. These four occupational rhythms help shape the whole of human organization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33798/abstract/6\">",
"     6",
"    </a>",
"    ]. The beneficial effect of maintaining some degree of balanced occupational activities, even during an illness, is the basis for the field of occupational therapy. Occupational therapies may be as varied as the occupations.",
"   </p>",
"   <p>",
"    Occupational therapies, like physical therapies, must be age-appropriate because the activities of children are a function of their age and level of maturity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The activities of newborn infants consist of sleeping, feeding, and growing. Feeding difficulty, which can lead to failure to thrive and altered behavior of the infant, as well as the parents, is one of the primary concerns of occupational therapists who work with infants. The awareness of feeding difficulties is increasing, in part because of the increased survival of preterm infants, many of whom have difficulty making the transition from tube to oral feeding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33798/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/4/21576?source=see_link\">",
"       \"Sucking and swallowing disorders in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Play, being a major activity for the growing child, is an important therapeutic tool for occupational therapists who work with growing children. Therapies that are presented through play will be more efficacious because they retain the child's attention for longer periods of time. In addition, play is a means for learning skills. As an example, the tactile and visual input experienced by a toddler who is playing and drawing with paint will facilitate sensorimotor development. Fine motor coordination can be acquired through activities such as dressing up and role-playing with dolls, whereby the child learns how to fasten (eg, buttons, zippers).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PLAY AND ART THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Play is not only a means for learning skills, but also for inciting children's exploratory curiosity and creativity. Exploration through play stimulates the development of imagination. Imagination facilitates their understanding and acceptance of life experiences, allowing them to make sense of their world. It also is a key player in their learning process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33798/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children spontaneously use play and art to cope with stresses they cannot control. Thus, play and art expression are used as therapies for sick children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33798/abstract/10\">",
"     10",
"    </a>",
"    ]. \"To the young child, play is life itself. Play fills mind and body, mentality, emotionality, and physical being,\" and it is \"through the variety and depth of play, [that] the child learns and grows\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33798/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Art, such as painting and drawing, is considered a visual language and a medium for self-expression, communication, conflict resolution, and emotional healing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33798/abstract/10\">",
"     10",
"    </a>",
"    ]. The outreach of play and art is multidimensional. Although the following descriptions were attributed to play [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33798/abstract/3\">",
"     3",
"    </a>",
"    ], many also pertain to art:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An opportunity for the child to grow and develop; to learn about physical, social, and emotional abilities and skills",
"     </li>",
"     <li>",
"      A mechanism for exploring and defining one's own motivation and achievement",
"     </li>",
"     <li>",
"      A pressure-free opportunity to perform [for] the process or [for] the feeling rather than [for] the product",
"     </li>",
"     <li>",
"      An imaginary world for mastery over unmanageable aspects of reality",
"     </li>",
"     <li>",
"      A foundation and builder of interpersonal relationships",
"     </li>",
"     <li>",
"      A way of learning and developing interests, skills in concentration and problem solving, and judgment",
"     </li>",
"     <li>",
"      An arena for learning about adolescent and adult roles, as well as role behaviors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Play and art expression can be used recreationally, therapeutically, and as specific therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33798/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. Recreational",
"    <span class=\"nowrap\">",
"     play/art",
"    </span>",
"    is used for personal satisfaction, pastime, or distraction from boredom. Therapeutic",
"    <span class=\"nowrap\">",
"     play/art,",
"    </span>",
"    as discussed earlier, is used in physical and occupational therapy to improve specific sensorimotor functions. It is used also as a means to alleviate stress to help prepare for medical procedures. As an example, to prepare a child for an intravenous catheter or a lumbar puncture, often a doll is used to show the child how the procedure will be done. Knowing what to expect helps a child handle a difficult process.",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Play/art",
"    </span>",
"    therapy, usually offered by a trained specialist, is considered psychotherapeutic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33798/abstract/10\">",
"     10",
"    </a>",
"    ]. It is used to communicate with the inner world of the child or adolescent and to assist in conflict resolution and emotional healing. It can be directive or nondirective, depending upon the style of the therapist and the needs of the young patient. The overall goal of play and art therapy is to safeguard the healthy psychological and mental development of the patient during times of illness, because an interruption of normal life experiences can affect growth and development.",
"   </p>",
"   <p>",
"    Play activity needs to be age-appropriate in order to reach out to young patients of all ages. Radio Lollipop, founded in 1978 in Great Britain, is an international charity that believes in \"the healing power of play\" to help stimulate children's imagination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33798/abstract/13\">",
"     13",
"    </a>",
"    ]. It is a 100 percent volunteer-driven program geared to all ages. Its format combines crafts, interactive games, and radio broadcasting of music, patients' discussions, and story time. Currently, 23 such programs exist throughout the world, with three in the United States. Radio Lollipop at Texas Children's Hospital in Houston is an on-site radio station broadcasting to patients' room via the hospital television system. Young patients can make their requests by visiting the fully equipped broadcasting studio or using the special Lollipop telephones at their bedside. Craft projects are offered to patients either as a group in an activity room or individually in their own rooms, and prizes are awarded for each project. Volunteer deejays play hits and children's favorites, take call-in requests, and put kids \"on air\" from the bedside or in the studio. Several evenings each week, broadcasts feature games, quizzes, art projects, and contests in which kids can win prizes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33798/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a general rule, play therapy falls under the supervision of Child Life services. \"Child life specialists are experts in child development, who promote effective coping through play, preparation, education, and self-expression activities [&hellip;]. Understanding that a child's well-being depends on the support of the family, &hellip;[they] provide information, support and guidance to parents, siblings, and other family members. They also play a vital role in educating caregivers, administrators, and the general public about the needs of children under stress\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33798/abstract/15\">",
"     15",
"    </a>",
"    ]. Their approach is holistic and preventive, following applied child development and family systems theory. In minimizing the negative impact of an illness, their goal is to maintain normalcy in growth, development, and family relationships. Using tools such as play, recreation, education, and self-expression, play therapy does not necessarily define specific functional outcomes; its success is based upon observations of \"external observable progression of play activity\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33798/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although painting and drawing are the more popular forms of art therapy, music and drama also are gaining attention as therapeutic interventions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33798/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The rhythmicity of music can entrain the patient, helping to relieve stress and anxiety. Music also is used as a diversion from pain or discomfort. Drama therapy aims to focus on the healthy aspects of the patient and to stimulate communication via voice and acting.",
"   </p>",
"   <p>",
"    Play and the arts (drawing, painting, music, drama) are not widely acknowledged as therapies because their beneficial effects are not evidence-based. However, this new field is expanding, as evidenced by the increased presence of child life professionals and art therapists in pediatric hospitals and their participation as active members of medical teams.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SOCIAL SERVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coping with long-term illness is difficult. In addition to the anxiety related to the outcome of the illness, patients and their families are faced with changes in their daily routines and unexpected financial burden. Social assistance can be offered by social workers",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chaplains.",
"   </p>",
"   <p>",
"    Clinical social workers are part of the medical team. They are professionals whose primary function is to help patients and their families deal with the impact of the child's illness and disruption of their normal lives. Their responsibilities are varied. They work one-on-one with the child",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    with the whole family. To help children adjust to their new situation, they can facilitate peer interaction so as to create a sense of community within the hospital. The latter can be further enhanced in",
"    <span class=\"nowrap\">",
"     encouraging/organizing",
"    </span>",
"    parent support groups to assist families to cope with this difficult period of time. They assist in organizing educational opportunities for school-age patients and in locating community resources for the family and the child's care following hospital discharge. They can provide immediate counseling themselves, but also can facilitate additional professional counseling if necessary.",
"   </p>",
"   <p>",
"    Family interaction is disrupted when a child is in the hospital, not only between the child and the family members, but also among family members themselves. A social worker is a neutral party in whom family members may more readily confide; the social worker is in a good position to help stabilize family relations at a time of crisis and to help parents acquire new caregiving and coping skills. The social worker should use special attention when explaining to a young patient what is happening and why he or she is in the hospital. As the medical condition of the patient evolves, social workers are liaisons between the",
"    <span class=\"nowrap\">",
"     patient/family",
"    </span>",
"    and the medical team or community agencies.",
"   </p>",
"   <p>",
"    In contrast to the clinical social worker, who focuses on the practical aspects of coping with illness, the chaplain cares for the emotional and spiritual needs of the patients and family. Although at first a chaplain may project a pastoral role, one of the primary functions of the hospital ministry is dialogue (ie, \"to listen to the voice of the suffering\") [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33798/abstract/19\">",
"     19",
"    </a>",
"    ]. Chaplains are called upon to play many roles: that of a doctor to explain an upcoming operation, a social worker to act as a family counselor, a priest to baptize a child, a professor to teach young clinicians, a parish pastor to act as a pastoral counselor, and a friend with whom the child can play and talk.",
"   </p>",
"   <p>",
"    Chaplains particularly strive to bring out the spirituality of their young patients, not in view of their religious beliefs but of how they perceive the meaning of their existence. Depending upon the age of the patient, spirituality may be as simple as what is important to them at that very moment (eg, \"I want to play a game\") to as complex as defining the significance of life. For children and adolescents, in particular, the chaplain may become the person \"who makes the hospital seem more human\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33798/abstract/20\">",
"     20",
"    </a>",
"    ], possibly because he or she is the furthest removed from their doctors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     WELL-BEING OF THE PRIMARY CAREGIVER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The auxiliary services in pediatrics described above are focused on the young patient. When working with family members, the concerns of social services are primarily geared toward the welfare of the child. However, awareness has been growing that the well-being of the primary caregiver, most often that of the mother, needs to be addressed at the same time. Indeed, to maintain the integrity of a healthy mother-child dyad, support for both partners is necessary. Although maternal stress results primarily from a child's sickness, it can be amplified by the mother&rsquo;s environment (eg, social support, coping skills) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33798/abstract/21\">",
"     21",
"    </a>",
"    ]. Evidence of the benefits of skin-to-skin holding (Kangaroo Mother Care) on parental stress and home environment has increased, strongly supporting such practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33798/abstract/22\">",
"     22",
"    </a>",
"    ]. The effects of maternal stress on the mother-child dyad may be most damaging when the infant is hospitalized for a prolonged period. Maternal attachment to the newborn may be threatened by the prolonged mother-infant separation and the emotional stress experienced by mothers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33798/abstract/23\">",
"     23",
"    </a>",
"    ]. This may threaten the integrity of a well-balanced mother-child dyad over the long-term. Mothers who do not have any medical issues following delivery are not patients per se and are seldom monitored by health care professionals after their routine postpartum follow-ups. Consequently, postpartum depression remains underdiagnosed and undertreated, although awareness is increasing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33798/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. The evaluation, treatment, and prevention of postpartum depression are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/11/20666?source=see_link\">",
"     \"Postpartum blues and depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H199251915\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The provision of medical care alone is not always sufficient for the well-being of hospitalized children. Recovery may be accelerated by the involvement of a variety of support services after the patient is stabilized.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The goal of auxiliary services is to restore as normal a life as possible by minimizing the negative impact of prolonged illness or disability. There are three main types of auxiliary services: physical and occupational therapy; play and art therapy; and social services. The need for specific services varies depending upon the severity and length of the child&rsquo;s illness, the child&rsquo;s developmental stage, and the family environment. (See",
"      <a class=\"local\" href=\"#H199252312\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The primary goals of physical and occupational therapy are to facilitate the child&rsquo;s adaptation to physical limitations provide rehabilitation. The approach to physical and occupational therapy differs based upon the physical and psychological development of the child. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Therapeutic services'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Play and art therapy are used to improve specific sensorimotor functions, alleviate stress, and prepare for medical procedures. The approach to play and art therapy differs depending upon the age and psychological development of the child. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Play and art therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Social workers help families cope with the impact of the child's illness and disruption of their normal lives. Chaplains focus on the emotional and spiritual needs of the patient and family. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Social services'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author wishes to express her gratitude to Sarah Fallon (Child Life), Carol Herron (Art and Medicine Program), Ingrid Kuznierczyk (Occupational Therapy), Amy Morris (Child Life), Jeri Thagard and Marcia Beretta (Social Service), and Chaplain D Wratchford at Texas Children's Hospital for their helpful comments in the preparation of this manuscript.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Shepherd RB. Physiotherapy in Paediatrics, 3rd ed, Butterworth-Heinemann, Oxford 1995.",
"    </li>",
"    <li>",
"     Physical Therapy for Children, 2nd ed, Saunders, Philadelphia 2000.",
"    </li>",
"    <li>",
"     Pediatric Occupational Therapy and Early Intervention, Andover Medical Publishers, Boston 1993.",
"    </li>",
"    <li>",
"     Maternal deprivation and growth suppression. In: Advances in Touch: New Implications in Human Development, Johnson &amp; Johnson, Skillman, NJ 1990. p.3.",
"    </li>",
"    <li>",
"     Loving Hands: The Traditional Art of Baby Massage, Knopf, New York 1976.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33798/abstract/6\">",
"      Meyer A. The philosophy of occupation therapy. Reprinted from the Archives of Occupational Therapy, Volume 1, pp. 1-10, 1922. Am J Occup Ther 1977; 31:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33798/abstract/7\">",
"      Lau C, Hurst N. Oral feeding in infants. Curr Probl Pediatr 1999; 29:105.",
"     </a>",
"    </li>",
"    <li>",
"     Egan K. Imagination in Teaching and Learning, University of Chicago Press, Chicago 1992.",
"    </li>",
"    <li>",
"     Sutton-Smith B. In Search of the Imagination. In: Imagination and Education, Egan K, Nadaner D (Eds), Teachers College Press, New York 1988.",
"    </li>",
"    <li>",
"     Malchiodi C. Medical Art Therapy with Children, Jessica Kingsley Publishing, London 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33798/abstract/11\">",
"      Evans MW. Play is life itself. The value of play for learning. Theory Into Practice 1974; 13:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33798/abstract/12\">",
"      Gibbons MB, Boren H. Stress reduction. A spectrum of strategies in pediatric oncology nursing. Nurs Clin North Am 1985; 20:83.",
"     </a>",
"    </li>",
"    <li>",
"     Radio Lollipop International www.radiolollipop.org (Accessed on August 12, 2009).",
"    </li>",
"    <li>",
"     Patients become deejays with Radio Lollipop. www.texaschildrenshospital.org/Kids/RadioLollipop/Default.aspx (Accessed on August 12, 2009).",
"    </li>",
"    <li>",
"     Child Life Council. www.childlife.org (Accessed on August 12, 2009).",
"    </li>",
"    <li>",
"     Jennings S. Introduction to Playtherapy, Jessica Kingsley Publishing, London 1999.",
"    </li>",
"    <li>",
"     Campbell D. The Mozart Effect: Tapping the Power of Music to Heal the Body, Strengthen the Mind, and Unlock the Creative Spirit, Avon Books, New York 1997.",
"    </li>",
"    <li>",
"     Jennings S, Cattanach A, Mitchell S, et al. The Handbook of Dramatherapy, Routledge, London 1994.",
"    </li>",
"    <li>",
"     Holst LE. Hospital Ministry: The Role of the Chaplain Today, Crossroad Publishing Company, New York 1985.",
"    </li>",
"    <li>",
"     Mitchell KR. Hospital Chaplain, The Westminster Press, Philadelphia 1966.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33798/abstract/21\">",
"      Singer LT, Fulton S, Kirchner HL, et al. Longitudinal predictors of maternal stress and coping after very low-birth-weight birth. Arch Pediatr Adolesc Med 2010; 164:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33798/abstract/22\">",
"      Tessier R, Charpak N, Giron M, et al. Kangaroo Mother Care, home environment and father involvement in the first year of life: a randomized controlled study. Acta Paediatr 2009; 98:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33798/abstract/23\">",
"      Lau C. The effect of stress on lactation--its significance for the preterm infant. Adv Exp Med Biol 2002; 503:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33798/abstract/24\">",
"      Beck CT. The effects of postpartum depression on child development: a meta-analysis. Arch Psychiatr Nurs 1998; 12:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33798/abstract/25\">",
"      Beck CT. Recognizing and screening for postpartum depression in mothers of NICU infants. Adv Neonatal Care 2003; 3:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33798/abstract/26\">",
"      Coates AO, Schaefer CA, Alexander JL. Detection of postpartum depression and anxiety in a large health plan. J Behav Health Serv Res 2004; 31:117.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2878 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-5088ACF45B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_0_33798=[""].join("\n");
var outline_f33_0_33798=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H199251915\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H199252312\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THERAPEUTIC SERVICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Physical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Occupational therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PLAY AND ART THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SOCIAL SERVICES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      WELL-BEING OF THE PRIMARY CAREGIVER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H199251915\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ACKNOWLEDGMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/2878\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2878|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/27/25011\" title=\"figure 1\">",
"      Auxiliary service interaction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/11/20666?source=related_link\">",
"      Postpartum blues and depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/4/21576?source=related_link\">",
"      Sucking and swallowing disorders in the newborn",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_0_33799="HCV hepatitis Light";
var content_f33_0_33799=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F53561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F53561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mild hepatitis in chronic HCV",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of a liver biopsy shows mild inflammation primarily limited to the portal area with focal periportal (piecemeal) necrosis in a patient with chronic hepatitis C virus (HCV) infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_0_33799=[""].join("\n");
var outline_f33_0_33799=null;
var title_f33_0_33800="Clinical manifestations of adrenal insufficiency in adults";
var content_f33_0_33800=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations of adrenal insufficiency in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/0/33800/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/0/33800/contributors\">",
"     Lynnette K Nieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/0/33800/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/0/33800/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/0/33800/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/0/33800/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/0/33800/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms and signs of adrenal insufficiency depend upon the rate and extent of loss of adrenal function, whether mineralocorticoid production is preserved, and the degree of stress. The onset of adrenal insufficiency is often very gradual and it may go undetected until an illness or other stress precipitates adrenal crisis.",
"   </p>",
"   <p>",
"    The acute and chronic clinical manifestations of adrenal insufficiency in adults are reviewed here. The causes, diagnosis, and treatment of the different forms of adrenal insufficiency are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40969?source=see_link\">",
"     \"Causes of primary adrenal insufficiency (Addison's disease)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/50/3880?source=see_link\">",
"     \"Causes of secondary and tertiary adrenal insufficiency in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/46/44777?source=see_link\">",
"     \"Diagnosis of adrenal insufficiency in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/47/42745?source=see_link\">",
"     \"Treatment of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ADRENAL CRISIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The syndrome of adrenal crisis (acute adrenal insufficiency) in adults may occur in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a previously undiagnosed patient with primary adrenal insufficiency who has been subjected to serious infection or other acute, major stress.",
"     </li>",
"     <li>",
"      In a patient with known primary adrenal insufficiency who does not take more glucocorticoid during an infection or other major illness, or has persistent vomiting caused by viral gastroenteritis or other gastrointestinal disorders.",
"     </li>",
"     <li>",
"      After bilateral adrenal infarction or bilateral adrenal hemorrhage.",
"     </li>",
"     <li>",
"      Less frequently in patients with secondary or tertiary adrenal insufficiency during acute stress, but is sometimes seen with acute cortisol deficiency due to pituitary infarction. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pituitary apoplexy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In patients who are abruptly withdrawn from doses of glucocorticoid that cause secondary adrenal insufficiency. Importantly, this includes not only oral but inhaled medications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The predominant manifestation of adrenal crisis is shock, but the patients often have nonspecific symptoms such as anorexia, nausea, vomiting, abdominal pain, weakness, fatigue, lethargy, fever, confusion or coma (",
"    <a class=\"graphic graphic_table graphicRef78490 \" href=\"mobipreview.htm?3/53/3931\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypoglycemia is a rare presenting manifestation of acute adrenal insufficiency; it is more common in secondary adrenal insufficiency caused by isolated corticotropin (ACTH) deficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/1-3\">",
"       1-3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with long-standing adrenal insufficiency who present in crisis may be hyperpigmented (due to chronic ACTH hypersecretion) and have weight loss, serum electrolyte abnormalities, and other manifestations of chronic adrenal insufficiency (",
"      <a class=\"graphic graphic_table graphicRef57534 \" href=\"mobipreview.htm?30/43/31420\">",
"       table 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The major hormonal factor precipitating adrenal crisis is mineralocorticoid, not glucocorticoid, deficiency, and the major clinical problem is hypotension. Thus, adrenal crisis can occur in patients who are receiving physiologic or even pharmacologic doses of synthetic glucocorticoid if their mineralocorticoid requirements are not met [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Furthermore, patients with secondary adrenal insufficiency, in whom aldosterone secretion is usually normal, rarely present in adrenal crisis. Although it is not primarily responsible, glucocorticoid deficiency can contribute to hypotension by causing decreased vascular responsiveness to angiotensin II and norepinephrine, decreased synthesis of renin substrate, and increased prostacyclin production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Primary adrenal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenal crisis most commonly presents as shock [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/62/6120?source=see_link\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\"",
"    </a>",
"    .) In addition to shock, other features may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abdominal tenderness, which may be elicited on deep palpation and is usually generalized. The cause is unknown; in adrenal insufficiency associated with polyglandular autoimmune failure, it may be a manifestation of the serositis associated with this disorder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fever, which is usually caused by infection, and may be exaggerated by hypocortisolemia. It should be assumed that",
"      <strong>",
"       fever indicates infection",
"      </strong>",
"      that must be identified and treated. The combination of abdominal pain and fever may lead to the incorrect diagnosis of an acute surgical abdomen with potentially catastrophic surgical exploration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, septic shock itself may occasionally cause transient relative adrenal insufficiency. This topic is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/20/24905?source=see_link&amp;anchor=H20#H20\">",
"     \"Evaluation of the response to ACTH in adrenal insufficiency\", section on 'Critical illness'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Bilateral adrenal injury, hemorrhage, and infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenal insufficiency is a potential complication of blunt trauma; cases have been recognized in the intensive care setting as a result of admission CT examinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/11\">",
"     11",
"    </a>",
"    ]. Adrenal crisis can also occur as a result of sudden bilateral adrenal necrosis caused by hemorrhage, emboli, sepsis or very rarely, adrenal vein thrombosis after a back injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. These patients do not have evidence of preexisting adrenal insufficiency. Before computed topography (CT) became widely available, the diagnosis of adrenal hemorrhage was usually made at autopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40969?source=see_link&amp;anchor=H10#H10\">",
"     \"Causes of primary adrenal insufficiency (Addison's disease)\", section on 'Hemorrhagic infarction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presenting symptoms and signs (and the frequency with which they occurred in one report) include hypotension or shock (more than 90 percent); abdominal, flank, back, or lower chest pain (86 percent); fever (66 percent), presumably a response to inflammation; anorexia, nausea, or vomiting (47 percent); neuropsychiatric symptoms such as confusion or disorientation (42 percent); and abdominal rigidity or rebound tenderness (22 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/12\">",
"     12",
"    </a>",
"    ]. Surprisingly, only about half the patients have hypotension before shock. The acute onset does not permit enough time for the patient to become hyperpigmented.",
"   </p>",
"   <p>",
"    Evidence of occult hemorrhage, such as a sudden fall in hemoglobin and hematocrit, and progressive hyperkalemia, hyponatremia, and volume contraction are other signs that should suggest the diagnosis.",
"   </p>",
"   <p>",
"    The major risk factors for adrenal hemorrhage or infarction are anticoagulant therapy or coagulopathy, and the postoperative state. In patients treated with an anticoagulant, the results of clotting tests are usually within the therapeutic range and spontaneous bleeding elsewhere is not evident [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because adrenal crisis is difficult to recognize clinically, it must be considered whenever these symptoms develop in a patient with one or more risk factors. Without appropriate therapy, shock progresses to coma and death. If the patient survives, adrenal function may rarely return to normal months later [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adrenal hemorrhage and often death has been associated with meningococcemia (Waterhouse-Friderichsen syndrome) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/15\">",
"     15",
"    </a>",
"    ], but Pseudomonas aeruginosa was the most common pathogen in 51 children dying of sepsis and bilateral adrenal hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40969?source=see_link&amp;anchor=H10#H10\">",
"     \"Causes of primary adrenal insufficiency (Addison's disease)\", section on 'Hemorrhagic infarction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pituitary apoplexy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenal crisis is rare in patients with secondary (pituitary) or tertiary (hypothalamic) adrenal insufficiency because function of the renin-angiotensin-aldosterone system is usually normal and hypovolemia is rare. These patients may have symptoms and signs of chronic adrenal insufficiency or of deficient secretion of other anterior pituitary hormones. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/39/31348?source=see_link\">",
"     \"Clinical manifestations of hypopituitarism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, adrenal crisis can occur when the loss of pituitary function is sudden and severe, as in pituitary apoplexy (pituitary infarction); the symptoms in these patients are due mainly to acute cortisol deficiency.",
"   </p>",
"   <p>",
"    Patients with pituitary apoplexy resulting from infarction of a large tumor usually complain of severe headache; they may also have acute visual loss or reduction in visual fields. However, because glucocorticoids have a role in maintaining peripheral vascular adrenergic tone, sudden loss of corticotropin (ACTH) secretion, particularly in conjunction with other serious illness, can lead to hypotension and shock [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/38/9833?source=see_link&amp;anchor=H11#H11\">",
"     \"Causes of hypopituitarism\", section on 'Pituitary apoplexy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CHRONIC PRIMARY ADRENAL INSUFFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic primary adrenal insufficiency may have symptoms and signs of glucocorticoid, mineralocorticoid and, in women, androgen deficiency. In contrast, patients with secondary or tertiary adrenal insufficiency usually have normal mineralocorticoid function.",
"   </p>",
"   <p>",
"    The diagnosis is usually obvious in patients with the full-blown syndrome of adrenal insufficiency. However, its onset is often insidious, with the gradual development of symptoms, most of which are nonspecific. In its early stage, therefore, diagnosis may be difficult. The clinical presentation of primary adrenal insufficiency is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/52/23369?source=see_link\">",
"     \"Causes and clinical manifestations of primary adrenal insufficiency in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Common features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common clinical features of chronic primary adrenal insufficiency are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef57534 \" href=\"mobipreview.htm?30/43/31420\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/2,18-20\">",
"     2,18-20",
"    </a>",
"    ]. Regardless of the immediate complaint, most patients with adrenal insufficiency have the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chronic malaise",
"     </li>",
"     <li>",
"      Lassitude",
"     </li>",
"     <li>",
"      Fatigue that is worsened by exertion and improved with bed rest",
"     </li>",
"     <li>",
"      Weakness that is generalized, not limited to particular muscle groups",
"     </li>",
"     <li>",
"      Anorexia",
"     </li>",
"     <li>",
"      Weight loss",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The weight loss is primarily due to anorexia, but dehydration may contribute. The amount of weight lost can vary from 2 to as much as 15 kg and may not become evident until adrenal failure is advanced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The patient may also be very sensitive to opioid, analgesic or sedative drugs, or may recover very slowly from illnesses or operations that do not precipitate adrenal crisis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Gastrointestinal complaints",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal symptoms, usually nausea, occasionally vomiting, abdominal pain, or diarrhea that may alternate with constipation, are common and correlate with the severity of adrenal insufficiency. Vomiting and abdominal pain often herald adrenal crisis, and the fluid loss due to vomiting or diarrhea may precipitate the crisis.",
"   </p>",
"   <p>",
"    The cause of gastrointestinal symptoms in adrenal insufficiency is not known. Esophagogastroduodenoscopy and gastrointestinal radiography are usually normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/21\">",
"     21",
"    </a>",
"    ], but gastric emptying may be delayed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/22\">",
"     22",
"    </a>",
"    ]. Peptic ulcer disease is rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/23\">",
"     23",
"    </a>",
"    ]. Steatorrhea responsive to glucocorticoid replacement has occasionally been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hypotension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular symptoms include postural dizziness or syncope. In most patients the blood pressure is low, but some have only postural hypotension. These symptoms are primarily due to volume depletion resulting from aldosterone deficiency. Serum concentrations of endothelin-1, a vasoconstrictive peptide, and of adrenomedullin, a vasodilator peptide, are reported to be increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32455?source=see_link\">",
"     \"Pathophysiology of heart failure: Neurohumoral adaptations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The contribution of these and other vasoactive agents to the hypotension of primary adrenal insufficiency, if any, is unknown. Glucocorticoids are necessary for adrenal medullary epinephrine synthesis, and patients with adrenal insufficiency have decreased serum epinephrine and compensatory increases in serum norepinephrine concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/27\">",
"     27",
"    </a>",
"    ]. This may cause slightly lower basal systolic blood pressure and an exaggerated increase in pulse rate in response to upright posture.",
"   </p>",
"   <p>",
"    Blood pressure control improves in patients with preexisting hypertension. Thus, the presence of hypertension is strong evidence against a diagnosis of adrenal insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Electrolyte abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyponatremia is found in 85 to 90 percent of patients, reflecting both sodium loss and volume depletion caused by mineralocorticoid deficiency and increased vasopressin secretion caused by cortisol deficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/17/25876?source=see_link\">",
"     \"Hyponatremia and hyperkalemia in adrenal insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Salt craving, sometimes with massive salt ingestion, is a distinctive feature in some patients. To make it more palatable, salt may be \"chased\" with lemon juice. Increased thirst for iced liquids is often reported.",
"   </p>",
"   <p>",
"    Hyperkalemia often associated with a mild hyperchloremic acidosis occurs in 60 to 65 percent of patients due to mineralocorticoid deficiency.",
"   </p>",
"   <p>",
"    Hypercalcemia is a rare occurrence. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/22/28007?source=see_link\">",
"     \"Etiology of hypercalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemia may occur after prolonged fasting or, rarely, several hours after a high-carbohydrate meal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. It is rare in adults in the absence of infection, fever, or alcohol ingestion. Hypoglycemia is more common in infants and children with primary adrenal insufficiency, patients with secondary adrenal insufficiency caused by isolated ACTH deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/2,3\">",
"     2,3",
"    </a>",
"    ], and patients with type 1 diabetes mellitus who develop adrenal insufficiency. In the latter patients, sensitivity to insulin is increased because of loss of the gluconeogenic effect of cortisol and the hyperglycemic effects of epinephrine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29638?source=see_link\">",
"     \"Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hyperpigmentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperpigmentation, which is evident in nearly all patients with primary adrenal insufficiency, is the most characteristic physical finding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/29\">",
"     29",
"    </a>",
"    ]. It is a consequence of cortisol deficiency, and is due to increased production of pro-opiomelanocortin, a prohormone that is cleaved into the biologically active hormones ACTH, melanocyte stimulating hormone (MSH) and others. The elevated MSH results in increased melanin synthesis, causing hyperpigmentation. In humans, melanin is synthesized in epidermal melanocytes lying just below the basal cells of the epithelium. The melanin is packaged in secretory granules, called melanosomes, which are phagocytosed by the basal cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/30\">",
"     30",
"    </a>",
"    ]. The entire POMC system is present in keratinocytes. In vitro, the POMC peptide, ACTH 1-17, may be a more potent stimulator of melanogenesis than MSH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. However, the relative roles of ACTH 1-17 and MSH in the hyperpigmentation observed in patients with adrenal insufficiency has not been studied.",
"   </p>",
"   <p>",
"    The resulting brown hyperpigmentation is generalized, but is most conspicuous in areas exposed to light (such as the face, neck, and backs of hands), areas exposed to chronic friction or pressure (such as the elbows, knees, spine, knuckles, waist [belt], midriff [girdle], and shoulders [brassiere straps]) (",
"    <a class=\"graphic graphic_picture graphicRef74922 \" href=\"mobipreview.htm?39/63/40951\">",
"     picture 1",
"    </a>",
"    ). Pigmentation is also prominent in the palmar creases, where it escapes being worn away by friction, and in areas that are normally pigmented, such as the areolae, axillae, perineum, and umbilicus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. However, since pigmentation of the palmar creases may be normal in darker-skinned individuals, comparison with other family members, and the presence or absence of additional abnormal pigmentation should be considered when evaluating this sign.",
"   </p>",
"   <p>",
"    Other patterns of hyperpigmentation include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patchy pigmentation on the inner surface of lips and the buccal mucosa along the line of dental occlusion (",
"      <a class=\"graphic graphic_picture graphicRef56401 \" href=\"mobipreview.htm?24/55/25456\">",
"       picture 2",
"      </a>",
"      ). It may also occur under the tongue, along the gingival border in patients with chronic periodontal disease, and on the hard palate.",
"     </li>",
"     <li>",
"      Generalized buccal, vaginal, and anal mucosal membrane hyperpigmentation is usually seen only in patients whose skin is normally pigmented, such as blacks and Native Americans. Hyperpigmentation in general is less noticeable in blacks, but generalized darkening may be evident.",
"     </li>",
"     <li>",
"      Existing freckles become darker, and numerous new brown or black freckles may appear.",
"     </li>",
"     <li>",
"      Scars acquired when primary adrenal insufficiency is present and untreated are permanently pigmented, those acquired earlier remain unpigmented, and those acquired during treatment do not become pigmented.",
"     </li>",
"     <li>",
"      The hair and nails may become darker, the nails showing longitudinal bands of darkening (",
"      <a class=\"graphic graphic_picture graphicRef57205 \" href=\"mobipreview.htm?4/31/4592\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The hyperpigmentation begins to fade within several days and largely disappears after a few months of adequate glucocorticoid therapy. Recovery is due to keratinization and then sloughing of the pigmented basal layer of the epidermis. Fading of hair and nails takes longer because the pigmented part of the hair shaft or nail grows out slowly, and scars never fade because the melanin is trapped in fibrous connective tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Sexual dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decreased axillary and pubic hair and loss of libido are common in women, in whom androgen production primarily occurs in the adrenal glands [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/19\">",
"     19",
"    </a>",
"    ]. These changes are unusual in men, in whom most androgen production occurs in the testes. The use of exogenous DHEA in patients with primary adrenal insufficiency is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/263?source=see_link&amp;anchor=H3#H3\">",
"     \"Dehydroepiandrosterone and its sulfate\", section on 'Use in adrenal insufficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Amenorrhea develops in about 25 percent of women. It may be due to the effects of chronic illness, weight loss, or autoimmune-mediated primary ovarian failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7817?source=see_link\">",
"     \"Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Musculoskeletal symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse myalgia and arthralgia are frequent symptoms in patients with adrenal insufficiency. Occasional patients have predominantly musculoskeletal symptoms and a few have flexion contractures of legs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Serum concentrations of muscle enzymes, muscle biopsy, and electromyography are usually normal. The myalgia and arthralgia disappear rapidly with glucocorticoid and mineralocorticoid replacement, but reversal of the contractures may take months and require orthopedic measures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Auricular-cartilage calcification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcification of the auricular cartilages may occur in long-standing primary or secondary adrenal insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/21,35,36\">",
"     21,35,36",
"    </a>",
"    ]. This finding occurs exclusively in men; it is thought to result from chronic cortisol deficiency, and does not improve with glucocorticoid replacement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Psychiatric manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with severe or long-standing adrenal insufficiency have psychiatric symptoms, including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mild to moderate organic brain syndrome in 5 to 20 percent",
"     </li>",
"     <li>",
"      Impairment of memory that can progress to confusion, delirium, and stupor",
"     </li>",
"     <li>",
"      Depression in 20 to 40 percent, manifested by apathy, poverty of thought, and lack of initiative",
"     </li>",
"     <li>",
"      Psychosis in 20 to 40 percent, manifested by social withdrawal, irritability, negativism, poor judgment, agitation, hallucinations, paranoid delusions, and bizarre or catatonic posturing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Perceptual disturbances, with increased sensitivity but impaired recognition and interpretation of auditory, tactile, gustatory, and olfactory stimuli, may also occur.",
"   </p>",
"   <p>",
"    These psychiatric symptoms occur early in the disease and may predate other symptoms, making the diagnosis of their cause difficult. Most of these symptoms disappear within a few days after glucocorticoid therapy is begun, but the psychosis may persist for several months. Improvement does not correlate with correction of electrolyte imbalance except, on occasion, in patients with severe hyponatremia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Vitiligo",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patchy, often bilaterally symmetrical areas of depigmented skin (vitiligo), the result of autoimmune destruction of dermal melanocytes, occur on the trunk or extremities in 10 to 20 percent of patients with autoimmune but not those with other causes of adrenal insufficiency&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/19,38\">",
"     19,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40969?source=see_link\">",
"     \"Causes of primary adrenal insufficiency (Addison's disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other findings associated with adrenal insufficiency include splenomegaly and lymphoid tissue hyperplasia, particularly of the tonsils. A high incidence of dental caries was reported when tuberculosis was the most common cause of adrenal insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, patients with polyglandular autoimmune syndrome type I often have chronic moniliasis of the mouth and nails that does not respond to glucocorticoid replacement therapy and responds to antifungal drug therapy poorly.",
"   </p>",
"   <p>",
"    Relative eosinophilia was reported to be a marker of adrenal insufficiency by George Thorn in 1948 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/39\">",
"     39",
"    </a>",
"    ]. Small subsequent series suggest that the eosinophil count is greater than",
"    <span class=\"nowrap\">",
"     500/mm3",
"    </span>",
"    in less than 20 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/40\">",
"     40",
"    </a>",
"    ]. Thus, while the presence of eosinophilia may suggest adrenal insufficiency, it does not have a high sensitivity and when found incidentally, other causes such as allergy or infection should be investigated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with AIDS, primary adrenal insufficiency occurs in up to 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/1\">",
"     1",
"    </a>",
"    ]. Fatigue is by far the most common presenting symptom. Only about one-third of the patients have hyperpigmentation and one-half have hyponatremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/50/22312?source=see_link\">",
"     \"Pituitary and adrenal gland dysfunction in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SECONDARY OR TERTIARY ADRENAL INSUFFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of secondary or tertiary adrenal insufficiency are similar to those of primary adrenal insufficiency, with a few major exceptions. Weakness, fatigability, myalgia, arthralgia, and psychiatric symptoms all can occur in patients with secondary adrenal insufficiency, indicating that these symptoms are caused by glucocorticoid rather than mineralocorticoid deficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/39/31348?source=see_link\">",
"     \"Clinical manifestations of hypopituitarism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major exceptions are that in secondary or tertiary adrenal insufficiency:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperpigmentation is not present because ACTH secretion is not increased.",
"     </li>",
"     <li>",
"      Dehydration is not present, and hypotension is less prominent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/2,3\">",
"       2,3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hyponatremia and volume expansion may be present, caused by an inappropriate increase in vasopressin secretion or action due to cortisol deficiency. The hyponatremia can occur early in the disease and may be the initial manifestation.",
"     </li>",
"     <li>",
"      Hyperkalemia is not present, reflecting the presence of aldosterone. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/17/25876?source=see_link\">",
"       \"Hyponatremia and hyperkalemia in adrenal insufficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gastrointestinal symptoms are less common [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/2\">",
"       2",
"      </a>",
"      ], suggesting that electrolyte disturbances may be involved in their etiology.",
"     </li>",
"     <li>",
"      Hypoglycemia is",
"      <strong>",
"       more common",
"      </strong>",
"      in secondary adrenal insufficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/2,42\">",
"       2,42",
"      </a>",
"      ]. This difference is not simply due to concomitant loss of growth hormone secretion, because it is the presenting feature in over one-third of the patients with isolated ACTH deficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33800/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]. One possible explanation is that the absence of dehydration and hypotension permits the patients to tolerate their illness longer and present with symptoms of chronic glucocorticoid deficiency, rather than mineralocorticoid deficiency.",
"     </li>",
"     <li>",
"      There may be clinical manifestations of a pituitary or hypothalamic tumor, such as symptoms and signs of deficiency of other anterior pituitary hormones, headache, or visual field defects.",
"     </li>",
"     <li>",
"      Patients with rare genetic syndromes of panhypopituitarism (for example, Pit-1 or PROP-1 mutations), may have additional extrapituitary manifestations. These are reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/38/9833?source=see_link&amp;anchor=H13#H13\">",
"       \"Causes of hypopituitarism\", section on 'Genetic diseases'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/26/20898?source=see_link\">",
"       \"Patient information: Addison&rsquo;s disease (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/19/11570?source=see_link\">",
"       \"Patient information: Adrenal crisis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/0/9220?source=see_link\">",
"       \"Patient information: Adrenal insufficiency (Addison's disease) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms and signs of adrenal insufficiency depend upon the rate and extent of loss of adrenal function, whether mineralocorticoid production is preserved, and the degree of stress. Although many of the symptoms are similar in patients with primary or",
"    <span class=\"nowrap\">",
"     secondary/tertiary",
"    </span>",
"    adrenal insufficiency, there are some important differences.",
"   </p>",
"   <p>",
"    <strong>",
"     Acute adrenal insufficiency",
"    </strong>",
"    &mdash;",
"    <strong>",
"    </strong>",
"    The syndrome of adrenal crisis (acute adrenal insufficiency) in adults may occur in the following situations (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Adrenal crisis'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a previously undiagnosed patient with primary adrenal insufficiency who has been subjected to serious infection or other acute, major stress.",
"     </li>",
"     <li>",
"      In a patient with known primary adrenal insufficiency who does not take more glucocorticoid during an acute infection (can occur during acute viral infections such as influenza) or other major illness, or has persistent vomiting caused by viral gastroenteritis or other gastrointestinal disorders.",
"     </li>",
"     <li>",
"      After bilateral adrenal infarction or bilateral adrenal hemorrhage.",
"     </li>",
"     <li>",
"      Rarely in patients with secondary or tertiary adrenal insufficiency, but is sometimes seen with acute cortisol deficiency due to pituitary apoplexy, or in patients withdrawn abruptly from suppressive doses of corticosteroids. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pituitary apoplexy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The predominant manifestation of adrenal crisis is shock, but the patients often have nonspecific symptoms such as anorexia, nausea, vomiting, abdominal pain, weakness, fatigue, lethargy, fever, confusion or coma (",
"      <a class=\"graphic graphic_table graphicRef78490 \" href=\"mobipreview.htm?3/53/3931\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Chronic adrenal insufficiency",
"    </strong>",
"   </p>",
"   <p>",
"    <strong>",
"     Primary",
"    </strong>",
"    &mdash;",
"    <strong>",
"    </strong>",
"    The most common clinical features of chronic primary adrenal insufficiency are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef57534 \" href=\"mobipreview.htm?30/43/31420\">",
"     table 2",
"    </a>",
"    ). Most patients present with chronic malaise, lassitude, fatigue (worsened by exertion and improved with bed rest), weakness, anorexia, and weight loss. Hypoglycemia is",
"    <strong>",
"     not",
"    </strong>",
"    common.",
"   </p>",
"   <p>",
"    Other clinical manifestations such as gastrointestinal symptoms, hypotension, electrolyte abnormalities, and hyperpigmentation are reviewed above. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Chronic primary adrenal insufficiency'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <strong>",
"     Secondary or tertiary",
"    </strong>",
"    &mdash;",
"    <strong>",
"    </strong>",
"    Many of the symptoms of secondary or tertiary adrenal insufficiency are the same as those for primary adrenal insufficiency, and are presumably due to glucocorticoid rather than mineralocorticoid deficiency. These include weakness, fatigue, myalgias, and arthralgias. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Secondary or tertiary adrenal insufficiency'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The major differences from primary adrenal insufficiency are that in secondary or tertiary adrenal insufficiency:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperpigmentation is not present because ACTH secretion is not increased.",
"     </li>",
"     <li>",
"      Dehydration is not present, and hypotension is less prominent.",
"     </li>",
"     <li>",
"      Hyponatremia and volume expansion may be present, but hyperkalemia is not (reflecting the presence of aldosterone).",
"     </li>",
"     <li>",
"      Gastrointestinal symptoms are less common, suggesting that electrolyte disturbances may be involved in their etiology.",
"     </li>",
"     <li>",
"      Hypoglycemia is",
"      <strong>",
"       more common",
"      </strong>",
"      in secondary adrenal insufficiency.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/1\">",
"      Pi&eacute;drola G, Casado JL, L&oacute;pez E, et al. Clinical features of adrenal insufficiency in patients with acquired immunodeficiency syndrome. Clin Endocrinol (Oxf) 1996; 45:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/2\">",
"      Burke CW. Adrenocortical insufficiency. Clin Endocrinol Metab 1985; 14:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/3\">",
"      Stacpoole PW, Interlandi JW, Nicholson WE, Rabin D. Isolated ACTH deficiency: a heterogeneous disorder. Critical review and report of four new cases. Medicine (Baltimore) 1982; 61:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/4\">",
"      Jacobs TP, Whitlock RT, Edsall J, Holub DA. Addisonian crisis while taking high-dose glucocorticoids. An unusual presentation of primary adrenal failure in two patients with underlying inflammatory diseases. JAMA 1988; 260:2082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/5\">",
"      Cronin CC, Callaghan N, Kearney PJ, et al. Addison disease in patients treated with glucocorticoid therapy. Arch Intern Med 1997; 157:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/6\">",
"      Saruta T, Suzuki H, Handa M, et al. Multiple factors contribute to the pathogenesis of hypertension in Cushing's syndrome. J Clin Endocrinol Metab 1986; 62:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/7\">",
"      Ohtani R, Yayama K, Takano M, et al. Stimulation of angiotensinogen production in primary cultures of rat hepatocytes by glucocorticoid, cyclic adenosine 3',5'-monophosphate, and interleukin-6. Endocrinology 1992; 130:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/8\">",
"      Jeremy JY, Dandona P. Inhibition by hydrocortisone of prostacyclin synthesis by rat aorta and its reversal with RU486. Endocrinology 1986; 119:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/9\">",
"      Bouachour G, Tirot P, Varache N, et al. Hemodynamic changes in acute adrenal insufficiency. Intensive Care Med 1994; 20:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/10\">",
"      Tucker WS Jr, Niblack GD, McLean RH, et al. Serositis with autoimmune endocrinopathy: clinical and immunogenetic features. Medicine (Baltimore) 1987; 66:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/11\">",
"      Castaldo ET, Guillamondegui OD, Greco JA 3rd, et al. Are adrenal injuries predictive of adrenal insufficiency in patients sustaining blunt trauma? Am Surg 2008; 74:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/12\">",
"      Rao RH, Vagnucci AH, Amico JA. Bilateral massive adrenal hemorrhage: early recognition and treatment. Ann Intern Med 1989; 110:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/13\">",
"      Xarli VP, Steele AA, Davis PJ, et al. Adrenal hemorrhage in the adult. Medicine (Baltimore) 1978; 57:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/14\">",
"      Streeten, DHP. Adrenal hemorrhage. Endocrinologist 1996; 6:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/15\">",
"      Migeon CJ, Kenny FM, Hung W, Voorhess ML. Study of adrenal function in children with meningitis. Pediatrics 1967; 40:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/16\">",
"      MARGARETTEN W, NAKAI H, LANDING BH. Septicemic adrenal hemorrhage. Am J Dis Child 1963; 105:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/17\">",
"      Randeva HS, Schoebel J, Byrne J, et al. Classical pituitary apoplexy: clinical features, management and outcome. Clin Endocrinol (Oxf) 1999; 51:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/18\">",
"      DUNLOP D. EIGHTY-SIX CASES OF ADDISON'S DISEASE. Br Med J 1963; 2:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/19\">",
"      Irvine, WJ, Barnes, EW. Adrenocortical insufficiency. Clin Endocrinol Metab 1972; 1:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/20\">",
"      Nerup J. Addison's disease--clinical studies. A report fo 108 cases. Acta Endocrinol (Copenh) 1974; 76:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/21\">",
"      JARVIS JL, JENKINS D, SOSMAN MC, THORN GW. Roentgenologic observations in Addison's disease; a review of 120 cases. Radiology 1954; 62:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/22\">",
"      Valenzuela GA, Smalley WE, Schain DC, et al. Reversibility of gastric dysmotility in cortisol deficiency. Am J Gastroenterol 1987; 82:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/23\">",
"      Tobin MV, Aldridge SA, Morris AI, et al. Gastrointestinal manifestations of Addison's disease. Am J Gastroenterol 1989; 84:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/24\">",
"      McBrien, DJ, Jones, RV, Creamer, B. Steatorrhoea in Addison's disease. Lancet 1963; 1:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/25\">",
"      Letizia C, Centanni M, Scuro L, et al. High plasma levels of endothelin-1 in untreated Addison's disease. Eur J Endocrinol 1996; 135:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/26\">",
"      Letizia C, Cerci S, Centanni M, et al. Circulating levels of adrenomedullin in patients with Addison's disease before and after corticosteroid treatment. Clin Endocrinol (Oxf) 1998; 48:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/27\">",
"      Zuckerman-Levin N, Tiosano D, Eisenhofer G, et al. The importance of adrenocortical glucocorticoids for adrenomedullary and physiological response to stress: a study in isolated glucocorticoid deficiency. J Clin Endocrinol Metab 2001; 86:5920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/28\">",
"      Armstrong L, Bell PM. Addison's disease presenting as reduced insulin requirement in insulin dependent diabetes. BMJ 1996; 312:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/29\">",
"      Barnett AH, Espiner EA, Donald RA. Patients presenting with Addison's disease need not be pigmented. Postgrad Med J 1982; 58:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/30\">",
"      Quevedo WC Jr. The control of color in mammals. Am Zool 1969; 9:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/31\">",
"      Tsatmali M, Ancans J, Yukitake J, Thody AJ. Skin POMC peptides: their actions at the human MC-1 receptor and roles in the tanning response. Pigment Cell Res 2000; 13 Suppl 8:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/32\">",
"      Rousseau K, Kauser S, Pritchard LE, et al. Proopiomelanocortin (POMC), the ACTH/melanocortin precursor, is secreted by human epidermal keratinocytes and melanocytes and stimulates melanogenesis. FASEB J 2007; 21:1844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/33\">",
"      Ebinger G, Six R, Bruyland M, Somers G. Flexion contractures: a forgotten symptom in Addison's disease and hypopituitarism. Lancet 1986; 2:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/34\">",
"      Shapiro MS, Trebich C, Shilo L, Shenkman L. Myalgias and muscle contractures as the presenting signs of Addison's disease. Postgrad Med J 1988; 64:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/35\">",
"      Barkan A, Glantz I. Calcification of auricular cartilages in patients with hypopituitarism. J Clin Endocrinol Metab 1982; 55:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/36\">",
"      Calvo Catal&aacute; J, Hortelano Mart&iacute;nez E, Gonz&aacute;lez-Cruz Cervellera MI, et al. [Calcification of auricular cartilages in a patient with adrenal insufficiency: presentation of a case and review of the literature]. An Med Interna 1994; 11:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/37\">",
"      Leigh H, Kramer SI. The psychiatric manifestations of endocrine disease. Adv Intern Med 1984; 29:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/38\">",
"      Zelissen PM, Bast EJ, Croughs RJ. Associated autoimmunity in Addison's disease. J Autoimmun 1995; 8:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/39\">",
"      THORN GW, FORSHAM PH. A test for adrenal cortical insufficiency; the response to pituitary andrenocorticotropic hormone. J Am Med Assoc 1948; 137:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/40\">",
"      Spry C. Eosinophilia in Addison's disease. Yale J Biol Med 1976; 49:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/41\">",
"      Skiest DJ, Keiser P. Clinical significance of eosinophilia in HIV-infected individuals. Am J Med 1997; 102:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33800/abstract/42\">",
"      Todd GR, Acerini CL, Ross-Russell R, et al. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 2002; 87:457.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 159 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-DE6246C94F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_0_33800=[""].join("\n");
var outline_f33_0_33800=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ADRENAL CRISIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Primary adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Bilateral adrenal injury, hemorrhage, and infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pituitary apoplexy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CHRONIC PRIMARY ADRENAL INSUFFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Common features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Gastrointestinal complaints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hypotension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Electrolyte abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hyperpigmentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Musculoskeletal symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Auricular-cartilage calcification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Psychiatric manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Vitiligo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SECONDARY OR TERTIARY ADRENAL INSUFFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/159\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/159|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/63/40951\" title=\"picture 1\">",
"      Hyperpigmentation in Addisons disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/55/25456\" title=\"picture 2\">",
"      Buccal hyperpigmentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/31/4592\" title=\"picture 3\">",
"      Pigmented nails in Addisons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/159|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/53/3931\" title=\"table 1\">",
"      Signs of adrenal crisis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/43/31420\" title=\"table 2\">",
"      Signs of adrenal insufficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/52/23369?source=related_link\">",
"      Causes and clinical manifestations of primary adrenal insufficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/38/9833?source=related_link\">",
"      Causes of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40969?source=related_link\">",
"      Causes of primary adrenal insufficiency (Addison's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/50/3880?source=related_link\">",
"      Causes of secondary and tertiary adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/39/31348?source=related_link\">",
"      Clinical manifestations of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/263?source=related_link\">",
"      Dehydroepiandrosterone and its sulfate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/46/44777?source=related_link\">",
"      Diagnosis of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/22/28007?source=related_link\">",
"      Etiology of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/20/24905?source=related_link\">",
"      Evaluation of the response to ACTH in adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/17/25876?source=related_link\">",
"      Hyponatremia and hyperkalemia in adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7817?source=related_link\">",
"      Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32455?source=related_link\">",
"      Pathophysiology of heart failure: Neurohumoral adaptations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/26/20898?source=related_link\">",
"      Patient information: Addison&rsquo;s disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/19/11570?source=related_link\">",
"      Patient information: Adrenal crisis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/0/9220?source=related_link\">",
"      Patient information: Adrenal insufficiency (Addison's disease) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29638?source=related_link\">",
"      Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/50/22312?source=related_link\">",
"      Pituitary and adrenal gland dysfunction in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/62/6120?source=related_link\">",
"      Shock in adults: Types, presentation, and diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/47/42745?source=related_link\">",
"      Treatment of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_0_33801="Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae";
var content_f33_0_33801=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/0/33801/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/0/33801/contributors\">",
"     Whitney A High, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/0/33801/contributors\">",
"     Milton H Nirken, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/0/33801/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/0/33801/contributors\">",
"     N Franklin Adkinson, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/0/33801/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/0/33801/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/0/33801/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/0/33801/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 21, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe idiosyncratic reactions, most commonly triggered by medications, which are characterized by fever and mucocutaneous lesions leading to necrosis and sloughing of the epidermis.",
"   </p>",
"   <p>",
"    SJS and TEN are distinguished chiefly by severity and percentage of body surface involved. The following three disorders have been distinguished:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stevens-Johnson syndrome - SJS is the less severe condition, in which skin sloughing is limited to less than 10 percent of the body surface (",
"      <a class=\"graphic graphic_picture graphicRef67632 graphicRef76141 graphicRef73805 \" href=\"mobipreview.htm?28/10/28842\">",
"       picture 1A-C",
"      </a>",
"      ). Mucous membranes are affected in over 90 percent of patients, usually at two or more distinct sites (ocular, oral, and genital).",
"     </li>",
"     <li>",
"      Toxic epidermal necrolysis - Toxic epidermal necrolysis (TEN) involves sloughing of greater than 30 percent of the body surface area (",
"      <a class=\"graphic graphic_picture graphicRef68458 graphicRef82150 graphicRef59418 graphicRef66134 \" href=\"mobipreview.htm?33/20/34122\">",
"       picture 2A-D",
"      </a>",
"      ). Mucous membranes are involved in nearly all cases.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       SJS/TEN",
"      </span>",
"      overlap syndrome -",
"      <span class=\"nowrap\">",
"       SJS/TEN",
"      </span>",
"      overlap syndrome describes patients with involvement of greater than 10 percent, but less than 30 percent of body surface area.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this review, the term",
"    <span class=\"nowrap\">",
"     \"SJS/TEN\"",
"    </span>",
"    is used to refer collectively to SJS, TEN, and",
"    <span class=\"nowrap\">",
"     SJS/TEN",
"    </span>",
"    overlap syndrome.",
"   </p>",
"   <p>",
"    This topic will discuss the management, prognosis, and long-term sequelae of",
"    <span class=\"nowrap\">",
"     SJS/TEN.",
"    </span>",
"    The clinical manifestations, pathogenesis, evaluation, diagnosis, and differential diagnosis are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/29/17882?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IMMEDIATE REMOVAL OF POSSIBLE TRIGGERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with SJS or TEN induced by medications, early identification and withdrawal of the offending agent improves prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/1\">",
"     1",
"    </a>",
"    ]. Any agents that could possibly be causative should be immediately discontinued in the setting of an adverse drug reaction with signs or symptoms suggestive of SJS or TEN. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/29/17882?source=see_link&amp;anchor=H6#H6\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\", section on 'Etiologies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following signs and symptoms, when present early in the course of an illness or apparent drug reaction, should alert clinicians to the possibility of",
"    <span class=\"nowrap\">",
"     SJS/TEN",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Confluent erythema (erythroderma)",
"     </li>",
"     <li>",
"      Facial edema or central facial involvement",
"     </li>",
"     <li>",
"      Skin pain",
"     </li>",
"     <li>",
"      Palpable purpura",
"     </li>",
"     <li>",
"      Skin necrosis",
"     </li>",
"     <li>",
"      Blisters",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      epidermal detachment",
"     </li>",
"     <li>",
"      Mucous membrane erosions and crusting",
"     </li>",
"     <li>",
"      Swelling of tongue",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The impact of early removal of the causative medications on mortality was evaluated in a 10-year observational study of 113 patients with TEN or SJS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/1\">",
"     1",
"    </a>",
"    ]. Logistic regression showed that the earlier the causative drug was removed, the better the prognosis (odds ratio [OR] = 0.69 for each day), after adjustment for confounding variables (age, maximum extent of detachment, admission year, human immunodeficiency virus status). In addition, causative drugs with long half-lives conferred an increased risk of death (OR = 4.9).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SUPPORTIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management involves multispecialty supportive care. Supportive care includes wound care, fluid and electrolyte management, nutritional support, ocular care, temperature management, pain control, and monitoring",
"    <span class=\"nowrap\">",
"     for/treatment",
"    </span>",
"    of superinfections. Ideally, a multispecialty team would include experts in critical care, plastic",
"    <span class=\"nowrap\">",
"     surgery/wound",
"    </span>",
"    care, dermatology, infectious disease, ophthalmology, and nutrition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Transfer to a burn unit",
"    </span>",
"    &nbsp;&mdash;&nbsp;SJS and TEN involve massive loss of the epidermis, and the principles of management are similar to those of burn victims. Some studies suggest that prognosis is better for patients transferred promptly to a burn care unit. As an example, a retrospective multicenter review of 199 patients with TEN treated at burn care centers documented an overall mortality rate of 32 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/3\">",
"     3",
"    </a>",
"    ]. In contrast, the mortality of the subset of patients initially cared for in other settings and transferred to a burn center more than one week after onset of disease was 51 percent. However, this type of study is prone to bias unless patients were carefully matched for the severity of their symptoms, which is unlikely.",
"   </p>",
"   <p>",
"    The decision to transfer to a burn unit should be guided by the experience and expertise of the individuals at a given facility in dealing with the spectrum of these disorders. Patients with extensive skin involvement should probably be transferred to a specialty center as promptly as possible, while this is not necessary in many mild cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Wound care",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extent of epidermal detachment should be evaluated daily and may be expressed as the percentage of body surface area that is involved (as for burns) (",
"    <a class=\"graphic graphic_figure graphicRef53352 \" href=\"mobipreview.htm?29/55/30583\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The optimal approach to wound care in",
"    <span class=\"nowrap\">",
"     SJS/TEN",
"    </span>",
"    has not been determined, and different approaches are used at various specialty centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. At some centers, wounds are surgically debrided and whirlpool therapy is used to remove necrotic epidermis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/7\">",
"     7",
"    </a>",
"    ]. In contrast, other centers use \"antishear\" wound care, in which the detached skin is left in place to act like a biologic dressing, potentially reducing painful debridements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/8\">",
"     8",
"    </a>",
"    ]. These two approaches (as practiced at expert centers) were found to result in equivalent rates of survival and re-epithelialization.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Non-adherent nanocrystalline gauze materials containing silver are being increasingly utilized in the care of SJS and TEN wounds, replacing petrolatum-impregnated gauze, although controlled trials comparing the two have not been performed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/9\">",
"       9",
"      </a>",
"      ]. Silver ions exert broad antimicrobial effects by interfering with the respiratory chain of cytochromes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/10\">",
"       10",
"      </a>",
"      ]. Such dressings may be left in place for longer durations (up to seven days), thereby decreasing the frequency of painful dressing changes.",
"     </li>",
"     <li>",
"      Biosynthetic skin substitutes, such as Biobrane, have also been used successfully [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fluidized air beds are useful when the patient's backside is significantly denuded, although these beds can make examination and care of those surfaces challenging [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Fluids and nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluid and electrolyte imbalances may occur due to increased transepidermal water loss, but replacement volumes are typically less than those of burn victims [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Room temperature should be increased to 30 to 32&ordm;C,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the use of heated-air body warmers to prevent excessive caloric expenditures due to epidermal loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/15\">",
"     15",
"    </a>",
"    ]. Oral feedings, via a nasogastric tube if necessary, should be initiated early. These may sometimes be introduced after just the second day of care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/16\">",
"     16",
"    </a>",
"    ]. Passage of a nasogastric tube should be performed with great care to minimize damage to affected mucous membranes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Ocular care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediate and ongoing attention to ocular involvement is recommended to avoid permanent ocular complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/17\">",
"     17",
"    </a>",
"    ]. We suggest obtaining a baseline ophthalmologic consultation when possible, with regular subsequent exams and additional consultation should eye complications be suspected at any point [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/18\">",
"     18",
"    </a>",
"    ]. At a minimum, daily lubrication with drops or ointments should be provided. Preservative-free preparations are preferred because preservatives can worsen ocular irritation. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Long-term sequelae'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with",
"    <span class=\"nowrap\">",
"     SJS/TEN",
"    </span>",
"    are at high risk of infection and sepsis remains a prominent cause of mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/15,19\">",
"     15,19",
"    </a>",
"    ]. However, prophylactic systemic antibiotics are NOT employed by the majority of burn units [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/3\">",
"     3",
"    </a>",
"    ]. Instead, management involves the following elements:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sterile handling and reverse-isolation procedures are essential [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/13,20\">",
"       13,20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19658?source=see_link\">",
"       \"General principles of infection control\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Repeated cultures of the skin, as well as blood, catheters, gastric, and urinary tubes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/1/34840?source=see_link\">",
"       \"Infections and antimicrobial resistance in the intensive care unit\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Signs of infection include increases in the quantity of bacteria cultured from a specific site, a sudden decrease in temperature, or general deterioration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/15\">",
"     15",
"    </a>",
"    ]. Antibiotic choice should be based upon specific culture data whenever possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/11\">",
"     11",
"    </a>",
"    ]. Infections with gram-negative rods, especially Pseudomonas aeruginosa, are particularly problematic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/16,21\">",
"     16,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/8/43142?source=see_link\">",
"     \"Pseudomonas aeruginosa skin, soft tissue, and bone infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Topical antibiotics are commonly used.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10964?source=see_link\">",
"     Silver sulfadiazine",
"    </a>",
"    is usually avoided because of the strong association of",
"    <span class=\"nowrap\">",
"     SJS/TEN",
"    </span>",
"    with sulfonamides, although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/53/42834?source=see_link\">",
"     silver nitrate",
"    </a>",
"    and newer silver-imbued nanocrystalline gauze materials are used successfully, as discussed previously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Wound care'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ADJUNCTIVE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beyond supportive care, there are no universally effective and established therapies for SJS or TEN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. However, there is extensive experience with several therapies, including glucocorticoids and intravenous gammaglobulin. Unfortunately, none have been adequately studied in controlled trials except",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    , which was found to be harmful. Controlled trials are essential because the prognosis with supportive care alone is favorable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/24\">",
"     24",
"    </a>",
"    ]. The most extensively used therapies are presented in this section and summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef66924 \" href=\"mobipreview.htm?16/60/17355\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The data regarding use of glucocorticoids in both SJS and TEN are mixed. Children and adults are considered separately:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     In children with SJS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrospective studies suggested that glucocorticoids may enhance morbidity in SJS. As an example, in one study of 32 children with SJS who were between 8 months and 14 years of age, the frequency of complications was greater among those who were treated with corticosteroids than those who were not (53 versus 0 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/25\">",
"     25",
"    </a>",
"    ]. Complications included infection (24 percent) and gastrointestinal bleeding (18 percent). In addition, duration of hospitalization was greater in the steroid-treated group (21 versus 13 days). Similar results were found in another retrospective study of 51 children (complication rate of 74 versus 28 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a subsequent randomized prospective trial in 16 children with SJS compared treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, within three days of the onset of rash) to supportive care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/27\">",
"     27",
"    </a>",
"    ]. Children in the treatment group had shortened duration of fever (four versus nine days) but no significant reduction in the period of skin eruption. Complications were minimal in both groups and consisted of superinfection of the skin lesions with S. aureus.",
"   </p>",
"   <p>",
"    Considering these studies together, we favor avoiding glucocorticoids in children with SJS, as this therapy can cause significant side effects and the overall prognosis is good with supportive care alone. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     In adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Larger studies are available analyzing the use of glucocorticoids in adults with",
"    <span class=\"nowrap\">",
"     SJS/TEN.",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In",
"      a series of 54 consecutive patients with SJS at one center, all received intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      at the time of diagnosis, at doses of 160 to 240 mg per day, with dose reduction at the first sign of clinical improvement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/28\">",
"       28",
"      </a>",
"      ]. There were no deaths or significant adverse outcomes.",
"     </li>",
"     <li>",
"      A large multinational retrospective study of 379 patients with SJS or TEN demonstrated a nonsignificant trend towards diminished mortality with the administration of glucocorticoids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/22\">",
"       22",
"      </a>",
"      ]. Patients received various glucocorticoids, including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      , and dexamethasone, either orally or intravenously, at widely varying doses. In countries where the mean maximum dose administered was relatively low (eg, the equivalent of 60 mg prednisone daily) the odds ratio (OR) for death was 0.9 (95% CI, 0.2-4.2), while in countries using higher mean maximum doses (eg, the equivalent of 250 mg prednisone daily) the OR for death was 0.2 (CI, 0.1-0.9).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, glucocorticoids theoretically increase the risk of sepsis, increase protein catabolism, and decrease the rate of epithelialization, and other studies have found that administration of systemic glucocorticoids was associated with increased morbidity and mortality, particularly if patients had TEN and received glucocorticoids for prolonged periods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/2,26,29-33\">",
"     2,26,29-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall, we are in favor of administration of glucocorticoids to adult patients in whom SJS has been diagnosed promptly (eg, within 24 to 48 hours), while recognizing that the evidence of clear benefit is inadequate. We suggest administering",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily (or an equivalent amount of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    ), and we do not continue therapy beyond four to seven days. We discontinue treatment sooner if there is any sign of infection.",
"   </p>",
"   <p>",
"    There is a clinical impression that glucocorticoids are more effective in cases in which the biopsy shows inflammatory changes (more lymphocytes), compared to those cases in which the biopsy is paucicellular, although this difference has not been formally documented and cannot be considered evidence-based.",
"   </p>",
"   <p>",
"    In contrast to adults with SJS, we do not treat adults with TEN with glucocorticoids because of concern for increased risk of sepsis, although the evidence of harm is not conclusive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Intravenous gammaglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data surrounding the use of intravenous immunoglobulin (IVIG) for SJS and TEN are limited and conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]. Most early reports involved administration of 1.0 to 1.5",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    in a single infusion. Later reports favored \"high-dose\" regimens of 1",
"    <span class=\"nowrap\">",
"     gram/kg",
"    </span>",
"    per day for three days (ie, a total dose of 3",
"    <span class=\"nowrap\">",
"     grams/kg),",
"    </span>",
"    although these are mostly small series of patients at single centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/38-43\">",
"     38-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest series in which IVIG was used was a multicenter, retrospective review of 48 patients with TEN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/41\">",
"     41",
"    </a>",
"    ]. The mean total dose was relatively high at 2.7",
"    <span class=\"nowrap\">",
"     grams/kg",
"    </span>",
"    (with doses ranging from 0.65 to 5.8",
"    <span class=\"nowrap\">",
"     grams/kg",
"    </span>",
"    divided over one to five days). Patients received IVIG seven days after onset of symptoms, on average. In 90 percent, skin and mucosal detachment ceased in two to three days and survival was 88 percent. Poorer outcomes were associated with the presence of underlying conditions, greater body surface area affected, lower doses of IVIG, and more days of symptoms before initiation of IVIG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/41,44\">",
"     41,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the multinational study of patients with SJS and TEN described previously, lower median doses of IVIG were administered (1.9",
"    <span class=\"nowrap\">",
"     grams/kg",
"    </span>",
"    [interquartile range 1.3 to 2.1",
"    <span class=\"nowrap\">",
"     g/kg]",
"    </span>",
"    supplied over one to seven days) and no benefit was apparent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, although the efficacy of IVIG for SJS or TEN has not been demonstrated convincingly, most studies of patients with severe SJS or TEN suggest benefit, particularly with higher doses. Therefore, we favor IVIG administration for adult patients with severe SJS or TEN and suggest total doses &gt;2 grams per kg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Combined therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids and IVIG have been administered in combination to patients with SJS and TEN, although the data are too limited to draw any conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/22\">",
"     22",
"    </a>",
"    ]. This is not our practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Plasmapheresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasmapheresis has been reported to be beneficial in several studies of patients with TEN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/45-49\">",
"     45-49",
"    </a>",
"    ]. Its use has not been reported in patients with SJS. Removal of a toxin, such as a drug, drug metabolite, or other cytotoxic mediator, has been proposed as a mechanism of action. However, at least one series demonstrated no difference in mortality, length of stay in hospital, or time to reepithelialization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/50\">",
"     50",
"    </a>",
"    ]. Thus, there is limited evidence of benefit and no evidence of harm in patients with TEN. We do not administer plasmapheresis at our center.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5835524\">",
"    <span class=\"h2\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports and a case series supporting the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    for SJS and TEN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/51-56\">",
"     51-56",
"    </a>",
"    ] led to the initiation of a pilot study in which 29 patients with SJS or TEN were treated with this agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/57\">",
"     57",
"    </a>",
"    ]. Although the pilot study detected a trend towards a reduction in the number of actual deaths compared with expected deaths, this difference was not statistically significant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/57\">",
"     57",
"    </a>",
"    ]. Additional studies are necessary to evaluate the efficacy and safety of cyclosporine in SJS and TEN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Harmful agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    is a potent inhibitor of TNF-alpha. When this cytokine was found to be potentially upregulated in TEN, thalidomide was proposed as a potential therapy. Treatment with thalidomide was studied in a double-blinded randomized placebo controlled study of TEN patients, but the trial had to be stopped because of increased mortality among those given the active agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/58\">",
"     58",
"    </a>",
"    ]. The exact mechanism by which thalidomide worsens TEN is not understood, but its use is firmly contraindicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Age at diagnosis and extent of skin detachment are the main prognostic factors for both SJS and TEN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/22,59\">",
"     22,59",
"    </a>",
"    ]. Children and young adults have a more favorable prognosis than older adults. In both SJS and TEN, early identification and withdrawal of the offending medication improves survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Immediate removal of possible triggers'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Stevens-Johnson syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall mortality rate for SJS has been reported to be as low as 1 to 3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Toxic epidermal necrolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For TEN, the prognosis is more guarded. More recent studies cite overall mortality rates of 25 to 35 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/19,44,45\">",
"     19,44,45",
"    </a>",
"    ]. The mortality rate in black patients exceeds that of white patients, although the reasons for this variation have not been studied. In a retrospective population-based analysis, the mortality rate for blacks compared to whites was 0.192 per 100,000 versus 0.025 per 100,000, leading to a mortality rate ratio of 7.57 (95% CI, 6.97-8.21) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prognostic scoring system (SCORTEN) based upon seven independent and easily measured clinical and laboratory variables has been validated for use on days one and three of hospitalization for TEN (",
"    <a class=\"graphic graphic_table graphicRef66897 \" href=\"mobipreview.htm?31/23/32123\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. Survival curves corresponding to the SCORTEN analysis on day one may be helpful when discussing a patient's prognosis with family members or medical staff (",
"    <a class=\"graphic graphic_figure graphicRef58211 \" href=\"mobipreview.htm?8/50/9006\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/63\">",
"     63",
"    </a>",
"    ]. The interpretation of Kaplan-Meier curves is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/18/22823?source=see_link\">",
"     \"Glossary of common biostatistical and epidemiological terms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In multivariate analysis, a SCORTEN of 3 to 6 (p = .003) and days to admission to a burn unit (&ge;5 days) (p = .027) were significant predictors of mortality during the postdischarge period for patients with TEN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     LONG-TERM SEQUELAE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term sequelae include dermatologic, mucosal, ocular, and pulmonary complications, which are increasingly reported as survival improves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dermatologic sequelae are common and include scarring, irregular pigmentation, eruptive nevi, abnormal regrowth of nails, and alopecia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/34,35,44,65\">",
"       34,35,44,65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sicca syndrome develops in up to 40 percent of survivors of TEN, and patients may fulfill criteria for Sjogren syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ophthalmologic sequelae include dry eye, photophobia, visual impairment, ingrown eyelashes (trichiasis), neovascularization of the cornea, keratitis, and corneal scarring leading to blindness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/65,67-69\">",
"       65,67-69",
"      </a>",
"      ]. Patients who experienced acute ocular involvement may be at increased risk for later-onset ocular disorders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/70\">",
"       70",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Long-term ocular complications were reported in a series of 30 patients with SJS or TEN and acute ocular involvement, of whom approximately one-half developed chronic ocular diseases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/71\">",
"       71",
"      </a>",
"      ]. Disorders included ocular surface failure, recurrent episodic inflammation, scleritis, and progressive conjunctival cicatrisation resembling pemphigoid, with new signs and symptoms appearing up to eight years after the acute",
"      <span class=\"nowrap\">",
"       SJS/TEN.",
"      </span>",
"      Patients should be advised that uncommon eye disorders can develop even years after the event and that new symptoms should trigger prompt evaluation by an ophthalmologist.",
"     </li>",
"     <li>",
"      Long-term pulmonary complications have also been reported, including chronic",
"      <span class=\"nowrap\">",
"       bronchitis/bronchiolitis",
"      </span>",
"      with obstructive change (including bronchiolitis obliterans and bronchiolitis obliterans organizing pneumonia), bronchiectasis, and obstructive disorders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/72\">",
"       72",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/43/24247?source=see_link\">",
"       \"Bronchiolitis in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/10/12458?source=see_link\">",
"       \"Clinical manifestations and diagnosis of bronchiectasis in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     FUTURE DRUG AVOIDANCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Patient education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who survive SJS or TEN attributed to a medication must be carefully educated about future avoidance and understand that reexposure may be fatal. Relevant information should be inscribed on a medical information bracelet or necklace and worn at all times. Patients should learn all the various names for the causative medication, be able to report that they have a history of SJS or TEN, and be able to recognize closely-related medications.",
"   </p>",
"   <p>",
"    Patients with SJS or TEN caused by anticonvulsants (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ) should be informed that other agents in the same class (ie, the \"aromatic\" anticonvulsants) may cause similar reactions in both the patient and their family members. This is reviewed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/17/41241?source=see_link&amp;anchor=H10#H10\">",
"     \"Drug eruptions\", section on 'Hypersensitivity syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Future use of related medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent",
"    <span class=\"nowrap\">",
"     SJS/TEN",
"    </span>",
"    with readministration of the culprit agent is documented in multiple case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/73-75\">",
"     73-75",
"    </a>",
"    ]. In addition, structurally similar drugs should also be avoided. One report described a patient with TEN triggered by the third generation cephalosporin",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    . During recovery, she was given",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    , a cabapenem antibiotic that also contains a beta lactam ring structure (",
"    <a class=\"graphic graphic_figure graphicRef79230 \" href=\"mobipreview.htm?22/52/23373\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/76\">",
"     76",
"    </a>",
"    ]. Skin lesions immediately recurred and new lesions developed on previously uninvolved skin. The patient decompensated and died shortly thereafter.",
"   </p>",
"   <p>",
"    Other types of reactions, in addition to recurrent",
"    <span class=\"nowrap\">",
"     SJS/TEN,",
"    </span>",
"    may also be possible if structurally-related drugs are readministered. One case report described a patient who survived TEN in response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    . Shortly after recovery, he was mistakenly given a dose of ceftriaxone again and developed symptoms similar to those of the initial reaction, which were successfully treated with glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/75\">",
"     75",
"    </a>",
"    ]. Four weeks later, he was treated with",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/13/35030?source=see_link\">",
"      piperacillin",
"     </a>",
"     /tazobactam",
"    </span>",
"    and developed anaphylaxis within 15 minutes of the first dose.",
"   </p>",
"   <p>",
"    The risk of recurrent",
"    <span class=\"nowrap\">",
"     SJS/TEN",
"    </span>",
"    with structurally distinct agents (within the same class of drugs) is unknown. As an example, data are lacking about the safety of administering",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/36/43592?source=see_link\">",
"     ketoprofen",
"    </a>",
"    (a proprionic acid NSAID) to a patient with past TEN to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/25/9625?source=see_link\">",
"     piroxicam",
"    </a>",
"    (an enolic acid NSAID). The clinician should also be aware that several different chemical groups of NSAIDs have been implicated in",
"    <span class=\"nowrap\">",
"     SJS/TEN",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef59655 \" href=\"mobipreview.htm?34/33/35356\">",
"     table 3",
"    </a>",
"    ). Therefore, until more information is available, we would favor avoidance of all NSAIDs, even those from distinct structural groups, in this situation. We are not aware of any case reports of patients with NSAID-induced",
"    <span class=\"nowrap\">",
"     TEN/SJS",
"    </span>",
"    who subsequently reacted to",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"      acetaminophen",
"     </a>",
"     /paracetamol,",
"    </span>",
"    although the latter agents have been independently implicated in",
"    <span class=\"nowrap\">",
"     SJS/TEN",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33801/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early recognition and immediate withdrawal of any potentially causative agents are critical first steps in the management of",
"      <span class=\"nowrap\">",
"       SJS/TEN.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Immediate removal of possible triggers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple specialists should be involved in the care of patients with",
"      <span class=\"nowrap\">",
"       SJS/TEN",
"      </span>",
"      when possible, including experts in critical care, plastic surgery, dermatology, infectious disease, ophthalmology, and nutrition. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Supportive care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with extensive desquamation, we suggest transfer to a burn unit if possible (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Transfer to a burn unit'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal approach to wound care has not been determined. Success has been reported with both repeated debridement of exfoliating skin, and \"anti-shear\" wound care, in which the necrotic skin is left in place to act as a biologic dressing. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Wound care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sepsis is the major cause of death. Sterile handling, infection control measures, topical antibiotic agents, and surveillance cultures of possible sites of superinfection are important components of prevention. Prophylactic systemic antibiotics are not utilized by the majority of burn centers, although antimicrobials should be administered at the first sign of infection, and choice of agent should be guided by specific culture data. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Supportive care should be the primary focus of management of",
"      <span class=\"nowrap\">",
"       SJS/TEN.",
"      </span>",
"      Beyond this, there is insufficient evidence to establish the benefit of any adjunctive therapies (",
"      <a class=\"graphic graphic_table graphicRef66924 \" href=\"mobipreview.htm?16/60/17355\">",
"       table 1",
"      </a>",
"      ). Systemic glucocorticoids and intravenous gammaglobulin (IVIG) are commonly used at many centers, although not all. Our approach is described below. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Adjunctive therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children (aged 16 years and younger) with SJS, we suggest NOT administering glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For adult patients with mild to moderate SJS, in whom the diagnosis has been made within a few days of symptom onset, we suggest high dose, short-term systemic glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We typically use",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , 2 mg per kg daily or an equivalent amount of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      , initiated as soon as possible after diagnosis. Glucocorticoids are discontinued after four to seven days or at the first sign of infection. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For pediatric and adult patients with severe SJS and TEN, we suggest IVIG (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We administer a dose of 1",
"      <span class=\"nowrap\">",
"       gram/kg",
"      </span>",
"      daily for three consecutive days. We do not administer glucocorticoids, due to concern about increasing the risk of sepsis, or employ plasmapheresis in the treatment of TEN. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Intravenous gammaglobulin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Glucocorticoids'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Plasmapheresis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mortality of SJS is 1 to 3 percent, while the mortality of TEN ranges from 25 to 35 percent. Predictors of mortality include older age at onset and greater extent of skin involvement. Long-term sequelae of the skin and eyes are common among survivors. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Prognosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Long-term sequelae'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/1\">",
"      Garcia-Doval I, LeCleach L, Bocquet H, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000; 136:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/2\">",
"      Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/3\">",
"      Palmieri TL, Greenhalgh DG, Saffle JR, et al. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil 2002; 23:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/4\">",
"      Ying S, Ho W, Chan HH. Toxic epidermal necrolysis: 10 years experience of a burns centre in Hong Kong. Burns 2001; 27:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/5\">",
"      Atiyeh BS, Dham R, Yassin MF, El-Musa KA. Treatment of toxic epidermal necrolysis with moisture-retentive ointment: a case report and review of the literature. Dermatol Surg 2003; 29:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/6\">",
"      Boorboor P, Vogt PM, Bechara FG, et al. Toxic epidermal necrolysis: use of Biobrane or skin coverage reduces pain, improves mobilisation and decreases infection in elderly patients. Burns 2008; 34:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/7\">",
"      Spies M, Sanford AP, Aili Low JF, et al. Treatment of extensive toxic epidermal necrolysis in children. Pediatrics 2001; 108:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/8\">",
"      Dorafshar AH, Dickie SR, Cohn AB, et al. Antishear therapy for toxic epidermal necrolysis: an alternative treatment approach. Plast Reconstr Surg 2008; 122:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/9\">",
"      Dalli RL, Kumar R, Kennedy P, et al. Toxic epidermal necrolysis/Stevens-Johnson syndrome: current trends in management. ANZ J Surg 2007; 77:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/10\">",
"      Dunn K, Edwards-Jones V. The role of Acticoat with nanocrystalline silver in the management of burns. Burns 2004; 30 Suppl 1:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/11\">",
"      Meneux E, Wolkenstein P, Haddad B, et al. Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases. Obstet Gynecol 1998; 91:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/12\">",
"      Heimbach DM, Engrav LH, Marvin JA, et al. Toxic epidermal necrolysis. A step forward in treatment. JAMA 1987; 257:2171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/13\">",
"      Pruitt BA Jr. Burn treatment for the unburned. JAMA 1987; 257:2207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/14\">",
"      Mayes T, Gottschlich M, Khoury J, et al. Energy requirements of pediatric patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Nutr Clin Pract 2008; 23:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/15\">",
"      Letko E, Papaliodis DN, Papaliodis GN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol 2005; 94:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/16\">",
"      Roujeau JC, Chosidow O, Saiag P, Guillaume JC. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol 1990; 23:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/17\">",
"      Chang YS, Huang FC, Tseng SH, et al. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. Cornea 2007; 26:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/18\">",
"      Imahara SD, Holmes JH 4th, Heimbach DM, et al. SCORTEN overestimates mortality in the setting of a standardized treatment protocol. J Burn Care Res 2006; 27:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/19\">",
"      Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987; 123:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/20\">",
"      Tompkins RG, Burke JF. Burn therapy 1985: acute management. Intensive Care Med 1986; 12:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/21\">",
"      Khoo AK, Foo CL. Toxic epidermal necrolysis in a burns centre: a 6-year review. Burns 1996; 22:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/22\">",
"      Schneck J, Fagot JP, Sekula P, et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008; 58:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/23\">",
"      Khalili B, Bahna SL. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol 2006; 97:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/24\">",
"      Hynes AY, Kafkala C, Daoud YJ, Foster CS. Controversy in the use of high-dose systemic steroids in the acute care of patients with Stevens-Johnson syndrome. Int Ophthalmol Clin 2005; 45:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/25\">",
"      Rasmussen JE. Erythema multiforme in children. Response to treatment with systemic corticosteroids. Br J Dermatol 1976; 95:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/26\">",
"      Ginsburg CM. Stevens-Johnson syndrome in children. Pediatr Infect Dis 1982; 1:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/27\">",
"      Kakourou T, Klontza D, Soteropoulou F, Kattamis C. Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children. Eur J Pediatr 1997; 156:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/28\">",
"      Tripathi A, Ditto AM, Grammer LC, et al. Corticosteroid therapy in an additional 13 cases of Stevens-Johnson syndrome: a total series of 67 cases. Allergy Asthma Proc 2000; 21:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/29\">",
"      Kim, PS, Goldfarb IW, Gaisford, JC, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: a pathophysiologic review with recommendations for a treatment protocol. J Burn Care Rehabil 1983; 4:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/30\">",
"      Halebian PH, Corder VJ, Madden MR, et al. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986; 204:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/31\">",
"      Kelemen JJ 3rd, Cioffi WG, McManus WF, et al. Burn center care for patients with toxic epidermal necrolysis. J Am Coll Surg 1995; 180:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/32\">",
"      Herndon DN. Toxic epidermal necrolysis: a systemic and dermatologic disorder best treated with standard treatment protocols in burn intensive care units without the prolonged use of corticosteroids. J Am Coll Surg 1995; 180:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/33\">",
"      Chave TA, Mortimer NJ, Sladden MJ, et al. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol 2005; 153:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/34\">",
"      Prins C, Vittorio C, Padilla RS, et al. Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicenter study. Dermatology 2003; 207:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/35\">",
"      Faye O, Roujeau JC. Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IV Ig): clinical experience to date. Drugs 2005; 65:2085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/36\">",
"      Metry DW, Jung P, Levy ML. Use of intravenous immunoglobulin in children with stevens-johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature. Pediatrics 2003; 112:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/37\">",
"      Morici MV, Galen WK, Shetty AK, et al. Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome. J Rheumatol 2000; 27:2494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/38\">",
"      Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/39\">",
"      Campione E, Marulli GC, Carrozzo AM, et al. High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis. Acta Derm Venereol 2003; 83:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/40\">",
"      Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience. Arch Dermatol 2003; 139:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/41\">",
"      Prins C, Kerdel FA, Padilla RS, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003; 139:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/42\">",
"      Tristani-Firouzi P, Petersen MJ, Saffle JR, et al. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol 2002; 47:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/43\">",
"      Stella M, Cassano P, Bollero D, et al. Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience. Dermatology 2001; 203:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/44\">",
"      French LE, Trent JT, Kerdel FA. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding. Int Immunopharmacol 2006; 6:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/45\">",
"      Sakellariou G, Koukoudis P, Karpouzas J, et al. Plasma exchange (PE) treatment in drug-induced toxic epidermal necrolysis (TEN). Int J Artif Organs 1991; 14:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/46\">",
"      Egan CA, Grant WJ, Morris SE, et al. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 1999; 40:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/47\">",
"      Kamanabroo D, Schmitz-Landgraf W, Czarnetzki BM. Plasmapheresis in severe drug-induced toxic epidermal necrolysis. Arch Dermatol 1985; 121:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/48\">",
"      Bamichas G, Natse T, Christidou F, et al. Plasma exchange in patients with toxic epidermal necrolysis. Ther Apher 2002; 6:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/49\">",
"      Chaidemenos GC, Chrysomallis F, Sombolos K, et al. Plasmapheresis in toxic epidermal necrolysis. Int J Dermatol 1997; 36:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/50\">",
"      Furubacke A, Berlin G, Anderson C, Sj&ouml;berg F. Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis? Intensive Care Med 1999; 25:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/51\">",
"      Ar&eacute;valo JM, Lorente JA, Gonz&aacute;lez-Herrada C, Jim&eacute;nez-Reyes J. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma 2000; 48:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/52\">",
"      Jarrett P, Rademaker M, Havill J, Pullon H. Toxic epidermal necrolysis treated with cyclosporin and granulocyte colony stimulating factor. Clin Exp Dermatol 1997; 22:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/53\">",
"      Zaki I, Patel S, Reed R, Dalziel KL. Toxic epidermal necrolysis associated with severe hypocalcaemia, and treated with cyclosporin. Br J Dermatol 1995; 133:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/54\">",
"      Sullivan JR, Watson A. Lamotrigine-induced toxic epidermal necrolysis treated with intravenous cyclosporin: a discussion of pathogenesis and immunosuppressive management. Australas J Dermatol 1996; 37:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/55\">",
"      Rai R, Srinivas CR. Suprapharmacologic doses of intravenous dexamethasone followed by cyclosporine in the treatment of toxic epidermal necrolysis. Indian J Dermatol Venereol Leprol 2008; 74:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/56\">",
"      Robak E, Robak T, G&oacute;ra-Tybor J, et al. Toxic epidermal necrolysis in a patient with severe aplastic anemia treated with cyclosporin A and G-CSF. J Med 2001; 32:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/57\">",
"      Valeyrie-Allanore L, Wolkenstein P, Brochard L, et al. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 2010; 163:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/58\">",
"      Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998; 352:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/59\">",
"      Roujeau JC, Guillaume JC, Fabre JP, et al. Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985. Arch Dermatol 1990; 126:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/60\">",
"      Risser J, Lewis K, Weinstock MA. Mortality of bullous skin disorders from 1979 through 2002 in the United States. Arch Dermatol 2009; 145:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/61\">",
"      Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/62\">",
"      Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States. Arch Dermatol 2004; 140:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/63\">",
"      Gu&eacute;gan S, Bastuji-Garin S, Poszepczynska-Guign&eacute; E, et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol 2006; 126:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/64\">",
"      Oplatek A, Brown K, Sen S, et al. Long-term follow-up of patients treated for toxic epidermal necrolysis. J Burn Care Res 2006; 27:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/65\">",
"      Sheridan RL, Schulz JT, Ryan CM, et al. Long-term consequences of toxic epidermal necrolysis in children. Pediatrics 2002; 109:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/66\">",
"      Moutsopoulos HM, Webber BL, Vlagopoulos TP, et al. Differences in the clinical manifestations of sicca syndrome in the presence and absence of rheumatoid arthritis. Am J Med 1979; 66:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/67\">",
"      Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/68\">",
"      Ortiz JE, Horn MS, Peterson HD. Toxic epidermal necrolysis-case report and review of the literature. Ann Plast Surg 1982; 9:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/69\">",
"      Power WJ, Ghoraishi M, Merayo-Lloves J, et al. Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum. Ophthalmology 1995; 102:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/70\">",
"      Gueudry J, Roujeau JC, Binaghi M, et al. Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 2009; 145:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/71\">",
"      De Rojas MV, Dart JK, Saw VP. The natural history of Stevens Johnson syndrome: patterns of chronic ocular disease and the role of systemic immunosuppressive therapy. Br J Ophthalmol 2007; 91:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/72\">",
"      Kamada N, Kinoshita K, Togawa Y, et al. Chronic pulmonary complications associated with toxic epidermal necrolysis: report of a severe case with anti-Ro/SS-A and a review of the published work. J Dermatol 2006; 33:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/73\">",
"      Roujeau JC. Immune mechanisms in drug allergy. Allergol Int 2006; 55:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/74\">",
"      Schmidt D, Kluge W. Fatal toxic epidermal necrolysis following reexposure to phenytoin: a case report. Epilepsia 1983; 24:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/75\">",
"      Lam A, Randhawa I, Klaustermeyer W. Cephalosporin induced toxic epidermal necrolysis and subsequent penicillin drug exanthem. Allergol Int 2008; 57:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33801/abstract/76\">",
"      Paquet P, Jacob E, Damas P, Pi&eacute;rard GE. Recurrent fatal drug-induced toxic epidermal necrolysis (Lyell's syndrome) after putative beta-lactam cross-reactivity: Case report and scrutiny of antibiotic imputability. Crit Care Med 2002; 30:2580.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2092 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-110.124.11.8-37D25D05A2-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_0_33801=[""].join("\n");
var outline_f33_0_33801=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IMMEDIATE REMOVAL OF POSSIBLE TRIGGERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SUPPORTIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Transfer to a burn unit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Wound care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Fluids and nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Ocular care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ADJUNCTIVE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - In children with SJS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - In adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Intravenous gammaglobulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Combined therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Plasmapheresis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5835524\">",
"      Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Harmful agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Stevens-Johnson syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Toxic epidermal necrolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      LONG-TERM SEQUELAE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      FUTURE DRUG AVOIDANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Patient education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Future use of related medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/2092\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/2092|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/55/30583\" title=\"figure 1\">",
"      Lund and browder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/50/9006\" title=\"figure 2\">",
"      TEN prognosis by SCORTEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/52/23373\" title=\"figure 3\">",
"      Beta lactam drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/2092|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/48/25345\" title=\"picture 1A\">",
"      Cutaneous changes of Stevens Johnson Syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/25/27030\" title=\"picture 1B\">",
"      Cutaneous findings of Stevens Johnson syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/7/30836\" title=\"picture 1C\">",
"      Mucosal changes in Stevens-Johnson syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/1/39953\" title=\"picture 2A\">",
"      Toxic epidermal necrolysis - back",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/18/35106\" title=\"picture 2B\">",
"      Toxic epidermal necrolysis - bullae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/27/13747\" title=\"picture 2C\">",
"      Toxic epidermal necrolysis - abdomen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/63/18419\" title=\"picture 2D\">",
"      Toxic epidermal necrolysis I",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/2092|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/60/17355\" title=\"table 1\">",
"      SJS TEN therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/23/32123\" title=\"table 2\">",
"      TEN SCORTEN criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/33/35356\" title=\"table 3\">",
"      Drugs assoc w SJS TEN",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/43/24247?source=related_link\">",
"      Bronchiolitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/10/12458?source=related_link\">",
"      Clinical manifestations and diagnosis of bronchiectasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/17/41241?source=related_link\">",
"      Drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/18/22823?source=related_link\">",
"      Glossary of common biostatistical and epidemiological terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/1/34840?source=related_link\">",
"      Infections and antimicrobial resistance in the intensive care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/8/43142?source=related_link\">",
"      Pseudomonas aeruginosa skin, soft tissue, and bone infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_0_33802="Statin myopathy";
var content_f33_0_33802=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Statin myopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/0/33802/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/0/33802/contributors\">",
"     Robert S Rosenson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/0/33802/contributors\">",
"     Steven K Baker, MSc, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/0/33802/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/0/33802/contributors\">",
"     Mason W Freeman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/0/33802/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/0/33802/contributors\">",
"     David M Rind, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/0/33802/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statins are the primary class of medication used to lower serum cholesterol concentration for both primary and secondary prevention of coronary disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=see_link\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Statins are both effective and generally safe. Although muscle toxicity remains a concern, severe myopathy is unusual, affecting perhaps 0.1 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/1\">",
"     1",
"    </a>",
"    ]. Muscle syndromes associated with statins, including myalgias and muscle injury, are discussed here. Other statin side effects are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32314?source=see_link\">",
"     \"Statins: Actions, side effects, and administration\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107312583\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism by which statins cause muscle toxicity is not well understood. They inhibit the conversion of HMG-CoA to mevalonic acid, which is an important early step in cholesterol synthesis.",
"   </p>",
"   <p>",
"    Statins can also decrease the synthesis of coenzyme Q10 (CoQ10, ubiquinone), which plays an important role in muscle cell energy production. It has been speculated that the reduction in CoQ10 may contribute to statin-induced muscle injury. Some studies have found that statins decrease plasma concentrations of CoQ10 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]; however, other studies have not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/5\">",
"     5",
"    </a>",
"    ], and studies have come to different conclusions about whether statin treatment decreases levels of CoQ10 in skeletal muscle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/4,6,7\">",
"     4,6,7",
"    </a>",
"    ]. Long-term treatment with simvastatin (10 to 40 mg daily for &gt;12 months) reduced CoQ10 content in skeletal muscles and decreased maximal mitochondrial oxidative phosphorylation capacity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/8\">",
"     8",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    One study found increased levels of plant sterols in skeletal muscle in patients treated with high-dose statins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/4\">",
"     4",
"    </a>",
"    ]. Specifically, sitosterol was increased by approximately 50 percent. The authors of the study proposed that these increased cellular levels could contribute to the muscle toxicity of statins. Beta-sitosterol is an activator of AMP-activated protein kinase, which inhibits acetyl-CoA carboxylase. This results in reduced fat synthesis and increased beta-oxidation. Preliminary evidence suggests that statin-intolerant patients demonstrate increased fatty acid oxidation (FAO) in response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    , implicating an intrinsic FAO abnormality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/9\">",
"     9",
"    </a>",
"    ]. Statins increase the expression of mitochondrial",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    acylcarnitine translocase and this effect may contribute to the alteration in FAO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Atrogin-1, a muscle-specific ubiquitin protein ligase, may play an important role in statin toxicity.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42312?source=see_link\">",
"     Lovastatin",
"    </a>",
"    induces expression of atrogin-1 in humans with statin myopathy and in several in vitro models; in the models, myopathy could be prevented by knockdown of atrogin-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/11\">",
"     11",
"    </a>",
"    ]. These and other proposed mechanisms require further experimental confirmation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107312605\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107312612\">",
"    <span class=\"h2\">",
"     Statin characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability to cause muscle injury appears to vary among the different statins. Myositis has been described in less than 0.5 percent overall, primarily occurring at higher doses. With",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    , for example, the incidence in clinical trials, in which patients were carefully monitored and some interacting drugs described below excluded, was 0.02 percent at 20",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    0.07 percent at 40",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    and 0.3 percent at 80",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H301173755\">",
"     'Dose limitations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The risk of myopathy appears to be lowest with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The safety of pravastatin (40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    was confirmed in an analysis of more than 112,000 patient-years of experience in three large controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/15\">",
"     15",
"    </a>",
"    ]. The incidence of serum CK elevations was not different from placebo, and there were no cases of confirmed clinical myositis or rhabdomyolysis.",
"   </p>",
"   <p>",
"    The possible differential sensitivity of statins on striated muscle has been evaluated in cell culture experiments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/16\">",
"     16",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     Simvastatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    reduced cell viability by 50 percent at concentrations of 1 and 5",
"    <span class=\"nowrap\">",
"     mcmol/L,",
"    </span>",
"    respectively; a much higher level of 300",
"    <span class=\"nowrap\">",
"     mcmol/L",
"    </span>",
"    was required with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    , suggesting less toxicity. The toxic effect of these agents on dividing myocytes may contribute to the development of myositis. The more hydrophilic statins, pravastatin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    , may have less penetration into muscle than the other more lipophilic statins. However, individual patient differences appear more likely than statin differences to affect statin uptake into muscle. (See",
"    <a class=\"local\" href=\"#H107312686\">",
"     'Patient characteristics'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32314?source=see_link&amp;anchor=H11#H11\">",
"     \"Statins: Actions, side effects, and administration\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to this difference in direct toxicity,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/56/9095?source=see_link\">",
"     pitavastatin",
"    </a>",
"    are also less likely to be involved with drug interactions since they are not extensively metabolized by CYP3A4 (",
"    <a class=\"graphic graphic_table graphicRef76992 \" href=\"mobipreview.htm?9/45/9950\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H301173662\">",
"     'Drug interactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"     Rosuvastatin",
"    </a>",
"    , like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    , is not extensively metabolized by CYP3A4 and is hydrophilic. In a trial in 17,802 apparently healthy adults, rates of muscle toxicity with rosuvastatin 20 mg daily were similar to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/17\">",
"     17",
"    </a>",
"    ]. There have been reports of rhabdomyolysis with rosuvastatin, particularly in myopathy-prone patients treated with doses higher than those recommended by the FDA product labeling, and product labeling in Europe highlights this risk, particularly at the highest dose of 40 mg daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107312679\">",
"    <span class=\"h2\">",
"     Pre-existing neuromuscular disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Underlying neuromuscular disorders may interact with statin therapy. In some cases statins can cause new neuromuscular disorders (see",
"    <a class=\"local\" href=\"#H262593031\">",
"     'Neuromuscular disorders'",
"    </a>",
"    below), however, others involve increased risk of toxicity in patients with known underlying neuromuscular disorders or the development of clinically-apparent disease in patients who had likely had preclinical disease before statins were initiated.",
"   </p>",
"   <p>",
"    Statins appear to have deleterious effects in patients with amyotrophic lateral sclerosis (ALS) and conditions that mimic ALS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/19\">",
"     19",
"    </a>",
"    ]. Cholesterol levels may play an important role, as dyslipidemia has been associated with prolonged survival in ALS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/20\">",
"     20",
"    </a>",
"    ]. ALS-associated hypermetabolism may require more cholesterol availability. Indeed, calorie restriction exacerbates motor symptoms and high fat intake improves survival in a mouse model of ALS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/21\">",
"     21",
"    </a>",
"    ]. Sterol bioavailability and cholesterol synthesis represent pivotal adaptive responses to extracellular stress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/22\">",
"     22",
"    </a>",
"    ]. Although the optimal lipid levels are unknown for patients with ALS, it is considered reasonable to withdraw statins and other hypolipidemics in patients who develop ALS.",
"   </p>",
"   <p>",
"    For genetically-based muscle disorders, statins are believed to trigger myogenic symptoms more readily than in healthy subjects, due to a reduced ability to compensate for drug-induced myotoxicity. In such patients, myopathic symptoms often persist after statin withdrawal, and this is a clinical indicator for electromyography and, potentially, muscle biopsy. It seems likely that the diverse neuromuscular phenotypes associated with statin use reflect multiple mechanisms acting either singly or synergistically.",
"   </p>",
"   <p>",
"    Reports of diseases that have become clinically apparent in patients on statins include myasthenia gravis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/23,24\">",
"     23,24",
"    </a>",
"    ], mitochondrial myopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/25-27\">",
"     25-27",
"    </a>",
"    ], McArdle disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/27-29\">",
"     27-29",
"    </a>",
"    ], acid maltase deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/30\">",
"     30",
"    </a>",
"    ], muscle phosphorylase b kinase deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/31\">",
"     31",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    -palmitoyl transferase deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/32\">",
"     32",
"    </a>",
"    ], rippling muscle disease (RMD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/33\">",
"     33",
"    </a>",
"    ], myotonic dystrophy types 1 and 2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/27,34\">",
"     27,34",
"    </a>",
"    ], cytoplasmic- and hyaline-body (myosin storage) myopathies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/35,36\">",
"     35,36",
"    </a>",
"    ], and motor neuronopathies (ie, Kennedy disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/27\">",
"     27",
"    </a>",
"    ] and amyotrophic lateral sclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/19\">",
"     19",
"    </a>",
"    ]).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107314231\">",
"    <span class=\"h2\">",
"     Hypothyroidism and other disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enhanced susceptibility to statin-associated myopathy occurs in patients with hypothyroidism, acute or chronic renal failure, and obstructive liver disease. In one hypothyroid patient, the myopathy resolved promptly after discontinuation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    and before initiation of thyroid hormone replacement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/37\">",
"     37",
"    </a>",
"    ], but in a second case the myopathy persisted until thyroid hormone was replaced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/38\">",
"     38",
"    </a>",
"    ]. These reports suggest that hypothyroidism may predispose to the development of statin-associated myopathy and that use of statins may \"unmask\" hypothyroid myopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/26/29093?source=see_link\">",
"     \"Hypothyroid myopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107312686\">",
"    <span class=\"h2\">",
"     Patient characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic factors appear to increase the risk of statin myopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/39\">",
"     39",
"    </a>",
"    ]. A genome-wide association study found that common variants of the SLCO1B1 gene, which encodes the organic anion transporting polypeptide 1B1 (OATP1B1) that mediates hepatic uptake of most statins, substantially increased or decreased the risk of myopathy in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/40\">",
"     40",
"    </a>",
"    ]. A subsequent randomized trial of statins found an association between a specific SLCO1B1 variant (SLCO1B1*5) and an increased risk of mild adverse events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As discussed, it remains unclear whether lipid-soluble statins penetrate the muscle membrane more readily than water-soluble statins, leading to increased risk for myopathy (see",
"    <a class=\"local\" href=\"#H107312612\">",
"     'Statin characteristics'",
"    </a>",
"    above). The discovery that organic anion transport polypeptide 2B1 (SLCO2B1) is expressed on the sarcolemma and mediates uptake of statins into the myocyte argues against a significant pathogenic role for passive diffusion of the fat-soluble statins. In addition to SLCO2B1, the multidrug resistance-associated proteins MRP1, MRP4, and MRP5 are also present in skeletal muscle and function as statin efflux transporters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/42\">",
"     42",
"    </a>",
"    ]. Ongoing research may clarify additional risk factors for myopathy related to statin transport phenomena in and out of skeletal muscle.",
"   </p>",
"   <p>",
"    Certain ethnic populations may be at increased risk for statin myopathy, at least with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    . Simvastatin prescribing information recommends caution when doses above 20 mg daily are used in Chinese patients who are also receiving niacin and states that such patients should not be treated with simvastatin 80 mg daily in combination with niacin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/43\">",
"     43",
"    </a>",
"    ]. In a large randomized trial in which all patients were treated with simvastatin 40 mg daily, participants from China had a higher rate of myopathy than patients from Europe (1.3 versus 0.4 events per 1000 patients per year) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/44\">",
"     44",
"    </a>",
"    ]. This risk was increased further in Chinese patients randomly assigned to treatment with",
"    <span class=\"nowrap\">",
"     niacin/laropiprant",
"    </span>",
"    rather than placebo (risk ratio [RR] 5.2 versus 1.5 in European patients). Of note, we suggest not treating any patients with simvastatin at doses above 40 mg daily even when used as monotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32314?source=see_link&amp;anchor=H5#H5\">",
"     \"Statins: Actions, side effects, and administration\", section on 'Potency'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107312713\">",
"    <span class=\"h2\">",
"     Concurrent drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increase in susceptibility to myopathy is substantially greater in patients receiving concurrent therapy with a number of drugs, particularly those that inhibit cytochrome P450 3A4 (CYP3A4) (",
"    <a class=\"graphic graphic_table graphicRef76992 \" href=\"mobipreview.htm?9/45/9950\">",
"     table 1",
"    </a>",
"    ), as well as with fibrates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/45\">",
"     45",
"    </a>",
"    ]. Furthermore, concurrent use of a drug or drug class that is independently considered a risk factor for myopathy (ie, glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    ) may further increase risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Although initial studies described cases of myopathy when niacin (nicotinic acid) was given with a statin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/48\">",
"     48",
"    </a>",
"    ], this complication appears to be uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/49-51\">",
"     49-51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The uptake, metabolism, and clearance of each statin differs, and therefore each statin is subject to different types of drug interactions.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     Simvastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    , and to a lesser extent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    are metabolized by CYP3A4.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"     Fluvastatin",
"    </a>",
"    clearance is partly dependent upon CYP2C9 metabolism whereas",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/56/9095?source=see_link\">",
"     pitavastatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    are cleared primarily by non CYP-450 transformations and affected by fewer significant interactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Hepatic uptake of rosuvastatin and pitavastatin is regulated by hepatocyte membrane transporters whose effect on statin concentrations can be altered by a smaller number of significant drug interactions.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       CYP3A4 drugs",
"      </strong>",
"      &mdash; Drugs and substances that inhibit cytochrome P450 3A4 (CYP3A4) (",
"      <a class=\"graphic graphic_table graphicRef76992 \" href=\"mobipreview.htm?9/45/9950\">",
"       table 1",
"      </a>",
"      ) can increase the risk of statin myopathy due to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42312?source=see_link\">",
"       lovastatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      , and to a lesser extent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/52\">",
"       52",
"      </a>",
"      ]. These include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/54-58\">",
"       54-58",
"      </a>",
"      ], macrolide antibiotics (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/59\">",
"       59",
"      </a>",
"      ], systemic-azole antifungals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/60\">",
"       60",
"      </a>",
"      ], and",
"      <span class=\"nowrap\">",
"       HIV/HCV",
"      </span>",
"      protease inhibitors including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      -boosted regimens (",
"      <a class=\"graphic graphic_table graphicRef76992 \" href=\"mobipreview.htm?9/45/9950\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/54,61,62\">",
"       54,61,62",
"      </a>",
"      ]. Drugs that do not inhibit CYP3A4 but are competitive CYP3A4 substrates may also have myopathic interactions with statins, as has been reported with myotoxicity with simvastatin and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      and elevated concentrations of simvastatin observed when taken with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/63,64\">",
"       63,64",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Calcium channel blockers",
"      </strong>",
"      &mdash; The nondihydropyridine calcium channel blockers",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      are moderate inhibitors of CYP3A4 metabolism. Manufacturer data indicate that, at a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      dose of 20 to 80",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      there is a 0.6 percent incidence of myopathy in patients also treated with verapamil (a value 10 times higher than seen in patients taking simvastatin without a calcium channel blocker) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/12\">",
"       12",
"      </a>",
"      ]. The risk is also increased when simvastatin is taken with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      , which is metabolized by CYP3A4 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/43,65\">",
"       43,65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       HIV and HCV protease inhibitors &mdash;",
"      </strong>",
"      HIV and HCV protease inhibitors (ie,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"       indinavir",
"      </a>",
"      , cobicistat-containing coformulations,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"       boceprevir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"       telaprevir",
"      </a>",
"      ) are potent inhibitors of CYP3A4. Thus, statins that are",
"      <strong>",
"       not",
"      </strong>",
"      highly dependent upon CYP3A4 for clearance (ie,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      or low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      ) have been usual choices for patients receiving protease inhibitors who require statin treatment. This practice is supported by manufacturer data and early case reports of myopathy and rhabdomyolysis in patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42312?source=see_link\">",
"       lovastatin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      in combination with HIV protease inhibitors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/66\">",
"       66",
"      </a>",
"      ]. Of the newer statins,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/56/9095?source=see_link\">",
"       pitavastatin",
"      </a>",
"      does not appear to interact with protease inhibitors, whereas",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"       rosuvastatin",
"      </a>",
"      can interact with some HIV protease inhibitors by a non-CYP mechanism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/67-69\">",
"       67-69",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      <strong>",
"      </strong>",
"      &mdash; Amiodarone and its metabolites can moderately inhibit CYP3A4 metabolism. Data from the manufacturer indicate that, at a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      dose of 80",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      there is a 6 percent risk of myopathy in patients also treated with amiodarone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/12\">",
"       12",
"      </a>",
"      ]. The risk of rhabdomyolysis in patients treated concurrently with amiodarone appears to be higher with simvastatin than with other statins [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Grapefruit juice",
"      </strong>",
"      &mdash; Grapefruit juice inhibits intestinal CYP3A4; however, daily consumption of eight ounces (240 mL) or less of grapefruit juice, or one-half of a grapefruit or less, is unlikely to increase the risk of an adverse interaction or muscle injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      <strong>",
"       &mdash;",
"      </strong>",
"      Cyclosporine is an inhibitor of CYPs 3A4, 2C9, and of the hepatocyte membrane efflux transporter organic anion transport protein (OATP), which regulates hepatic uptake of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"       fluvastatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"       rosuvastatin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/56/9095?source=see_link\">",
"       pitavastatin",
"      </a>",
"      . Coadministration of cyclosporine can increase concentrations of fluvastatin twofold and rosuvastatin and pitavastatin by 3&ndash; to 10-fold or more [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/68,72-74\">",
"       68,72-74",
"      </a>",
"      ]. Cyclosporine has been safely administered with fluvastatin doses of up to 40 mg per day [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/75\">",
"       75",
"      </a>",
"      ]. Rosuvastatin and pitavastatin are dose limited or contraindicated with cyclosporine, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Fibrates",
"      </strong>",
"      &mdash; Fibrates are independently associated with muscle toxicity. An increased risk of muscle toxicity, as high as 1 to 5 percent, has been described with the administration of some statins (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42312?source=see_link\">",
"       lovastatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      ) with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"       gemfibrozil",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/55,76-78\">",
"       55,76-78",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"       Colchicine",
"      </a>",
"      <strong>",
"       &mdash;",
"      </strong>",
"      Myopathy is an infrequent adverse effect of colchicine treatment and several cases have been reported following its coadministration with a statin, particularly in the setting of renal insufficiency. Multiple mechanisms seem to be involved as the interaction has been reported with a variety of statins, including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/63,79\">",
"       63,79",
"      </a>",
"      ]. &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/9/21651?source=see_link\">",
"       Fusidic acid",
"      </a>",
"      &mdash; Several cases of rhabdomyolysis have been reported following coadministration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      with fusidic acid, an antimicrobial available primarily outside the United States [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/80-86\">",
"       80-86",
"      </a>",
"      ]. The interaction appears to cause significant elevation in levels of both the statin and fusidic acid and could be due to inhibition of glucuronidation, but the exact mechanism is unknown.",
"     </li>",
"     <li>",
"      <strong>",
"       Niacin",
"      </strong>",
"      &mdash; Early reports suggested an elevated risk of myopathy with combination niacin and statin treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/48\">",
"       48",
"      </a>",
"      ], and this is reflected in longstanding warnings found in some of the statin drug labels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/55,64\">",
"       55,64",
"      </a>",
"      ]. This complication appears to be uncommon, and the risk of myopathy has seemed similar to that of either agent taken separately [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/49-51,87\">",
"       49-51,87",
"      </a>",
"      ]. However, in a large randomized trial in patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      , the combination of niacin and laropiprant increased the risk of definite myopathy (1.6 versus 0.4 events per 1000 patients per year; risk ratio [RR] 4.4, 95% CI 2.6-7.5) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/44\">",
"       44",
"      </a>",
"      ]. The risk was particularly increased in participants from China (see",
"      <a class=\"local\" href=\"#H107312686\">",
"       'Patient characteristics'",
"      </a>",
"      above). It is uncertain whether niacin alone carries the same increased myopathy risk as",
"      <span class=\"nowrap\">",
"       niacin/laropiprant,",
"      </span>",
"      however, this trial was much larger than prior studies and has the potential to have detected an interaction between niacin and statins that could have been missed in earlier smaller studies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Management of these drug interactions, including choice of statin, dose limitations, and use of specific fibrates, is discussed below (see",
"    <a class=\"local\" href=\"#H301173662\">",
"     'Drug interactions'",
"    </a>",
"    below). For more detailed information about specific statin interactions refer to the Lexi-Interact program included with UpToDate. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107312769\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies suggest that physical exertion increases the risk of myopathy in patients taking statins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/88\">",
"     88",
"    </a>",
"    ]; however, the mechanism for this is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/89\">",
"     89",
"    </a>",
"    ], and the association has not been consistently found across trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. Exercise can induce rhabdomyolysis in patients with metabolic muscle disease and may be a risk factor for rhabdomyolysis in patients taking statins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/92\">",
"     92",
"    </a>",
"    ]. We do not ask patients who are taking statins to limit exercise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MYOPATHIC SYNDROMES ASSOCIATED WITH STATIN THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myopathic syndromes associated with statin therapy range from myalgias to myositis to overt rhabdomyolysis, which may be associated with acute renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/54,93\">",
"     54,93",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While the diagnosis of more severe myopathic syndromes is typically straightforward based on a temporal association and laboratory findings, in some patients distinguishing benign myalgias due to statin therapy from other causes of muscle pain and weakness can be difficult.",
"   </p>",
"   <p>",
"    The terminology surrounding statin myopathy is imprecise, and a framework has been proposed (",
"    <a class=\"graphic graphic_table graphicRef81799 \" href=\"mobipreview.htm?32/23/33147\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/93\">",
"     93",
"    </a>",
"    ]. This topic uses the framework set out in the sections below that is currently more widely recognized.",
"   </p>",
"   <p>",
"    Information about muscle injury and statins has come both from large clinical trials of statin therapy and from observational studies of statins in clinical use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/94\">",
"     94",
"    </a>",
"    ]. A meta-analysis of 35 randomized trials of statins found no excess risk of myalgias, creatine kinase elevations, rhabdomyolysis, or discontinuation of therapy versus placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/45\">",
"     45",
"    </a>",
"    ]. However, experience in clinical practice suggests that muscle side effects are relatively common, including side effects requiring discontinuation of statin therapy. The explanation for this difference is uncertain, but may relate to selection criteria in randomized trials that limit the ability to generalize their results to the side effect profiles seen in a broader population of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of clinically-significant myopathy is substantially increased in patients treated with certain other drugs, particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    , azole antifungals, and certain macrolide antibiotics. (See",
"    <a class=\"local\" href=\"#H107312713\">",
"     'Concurrent drug therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Time course of myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of muscle symptoms is usually within weeks to months after the initiation of statin therapy but may occur at any time during treatment. As an example, a review of 44 cases of statin-associated myopathy found a mean duration of therapy before symptom onset of 6.3 months (range 0.25 to 48.0 months); approximately two-thirds of patients had onset of symptoms within six months of starting therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/96\">",
"     96",
"    </a>",
"    ]. Myalgias and weakness resolve and serum creatine kinase concentrations return to normal over days to weeks after discontinuation of the drug. In the above study, the mean time to resolution of symptoms in 43 patients who discontinued statin therapy was 2.3 months (range 0.25 to 14.0 months); 58 percent had resolution of symptoms within one month and 93 percent had resolution within six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No other treatment is necessary except for supportive care in patients who develop rhabdomyolysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Myalgias",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107311521\">",
"    <span class=\"h3\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of \"benign\" myalgias in large clinical trials of statin therapy ranged from 2 to 11 percent, a value not different from placebo-treated controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/55,97-99\">",
"     55,97-99",
"    </a>",
"    ]. Similarly, an elevation in serum CK above normal occurred in approximately 30 percent of both statin-treated and placebo-treated groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, we have seen patients who had new onset myalgias and fatigability temporally related to statin therapy. The symptoms gradually resolved with statin discontinuation and recurred with statin reintroduction. Consistent with this, a six-month randomized trial in 420 healthy adults designed to examine the effects of statin therapy on muscle function found a higher incidence of myalgia in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    80 mg daily than with placebo (9.3 versus 4.6 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107311528\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statin-induced myalgia typically presents as proximal, symmetric muscle weakness and soreness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/101\">",
"     101",
"    </a>",
"    ]. There may be muscle tenderness and there may be functional impairments such as difficulty raising the arms above the head, arising from a seated position, or climbing stairs; these symptoms are often described as fatigue or tiredness by the patient. Less often the discomfort is asymmetric. Other reported symptoms include cramping (including nocturnal cramping) and tendon pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/101\">",
"     101",
"    </a>",
"    ]. Some patients, but not all, have elevations in serum CK. (See",
"    <a class=\"local\" href=\"#H107311578\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although there have been concerns about the effects of statin therapy on exercise tolerance even in the absence of other symptoms, in the trial discussed above, no statistically-significant differences were seen in muscle strength, muscle endurance, or aerobic performance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107311578\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of symptomatic statin myopathy with laboratory abnormalities (ie, elevated serum CK) is typically straightforward and based on a temporal association for both onset with initiation of statin therapy and resolution with statin withdrawal.",
"   </p>",
"   <p>",
"    However, some patients can have muscle symptoms from statin therapy without an elevation in serum CK. This issue was directly addressed in a crossover study in which 4 of 21 blinded patients who had muscle symptoms while taking a statin (aching, weakness, decreased exercise tolerance) could distinguish statin therapy from placebo because of reproducible muscle symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/25\">",
"     25",
"    </a>",
"    ]. Strength testing confirmed muscle weakness during statin therapy that resolved during placebo treatment; unblinded review of muscle biopsies showed evidence of mitochondrial dysfunction that also reversed with cessation of therapy. Serum statin concentrations were not inappropriately elevated.",
"   </p>",
"   <p>",
"    There are many other common causes of muscle pain and weakness, including overuse and other injuries, and pain syndromes such as fibromyalgia and myofascial pain syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42472?source=see_link\">",
"     \"Overview of soft tissue rheumatic disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8056?source=see_link\">",
"     \"Clinical manifestations and diagnosis of fibromyalgia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35608?source=see_link\">",
"     \"Differential diagnosis of fibromyalgia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/23/2424?source=see_link\">",
"     \"Approach to the patient with myalgia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Distinguishing among these is typically based on a careful history and trials of cessation and reintroduction of statin therapy. Even with this, in some patients it will be difficult to be certain whether muscle symptoms are due to statin therapy. The sensitivity and specificity of muscle biopsy for statin myopathy are unknown, and we do not typically use this test clinically. A general approach to patients with myalgia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/23/2424?source=see_link\">",
"     \"Approach to the patient with myalgia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical judgment is necessary in interpreting elevated CK levels in patients on statins. CK elevations can be related to hypothyroidism or muscle injury during sports (running, diving for a volleyball, hockey), and patients who engage in high-impact sports should be advised to have a CK measured before engaging in exercise that day. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/56/36745?source=see_link\">",
"     \"Muscle enzymes in the evaluation of neuromuscular diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Myositis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically-significant myopathy, defined as a serum CK elevation more than 10 times normal in association with muscle symptoms, occurred in less than 0.5 percent of patients in the large clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/55,97-99\">",
"     55,97-99",
"    </a>",
"    ]. A review of one year of records for 1014 patients taking statins in a primary care practice found that 0.9 percent of patients had CK elevations more than five times normal, and none of these appeared to be related to statin use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/102\">",
"     102",
"    </a>",
"    ]. Fourteen patients (2.1 percent) had elevations 2.5 to 5.0 times normal and, of these, two appeared to be potentially related to statin use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Rhabdomyolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation and diagnosis of rhabdomyolysis is discussed separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    ). Treatment includes cessation of statin therapy and supportive management. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21847?source=see_link\">",
"     \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In large clinical trials, massive rhabdomyolysis with acute renal failure was not seen in patients who did not have other risk factors. Rhabdomyolysis has primarily been seen when a statin is given concurrently with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    (see",
"    <a class=\"local\" href=\"#H107312713\">",
"     'Concurrent drug therapy'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/76,103,104\">",
"     76,103,104",
"    </a>",
"    ]. In addition, there have been case reports of rhabdomyolysis in patients taking statins in combination with niacin, macrolide antibiotics,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , antifungal medications, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other possible predisposing factors include hypothyroidism and inflammatory myopathies (polymyositis and dermatomyositis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/92,106,107\">",
"     92,106,107",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/26/29093?source=see_link&amp;anchor=H9#H9\">",
"     \"Hypothyroid myopathy\", section on 'Rhabdomyolysis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32314?source=see_link&amp;anchor=H13#H13\">",
"     \"Statins: Actions, side effects, and administration\", section on 'Muscle injury'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One study examined claims data from 11 managed care plans that included 252,460 patients treated with lipid lowering agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/13\">",
"     13",
"    </a>",
"    ]. The average incidence of hospitalization for rhabdomyolysis was 0.44 per 10,000 patient-years (95% CI 0.20-0.84) for patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    monotherapy. Although the study did not find a statistical difference in the incidence of rhabdomyolysis among these three statins, no cases of rhabdomyolysis were seen with pravastatin. The incidence was higher with cerivastatin monotherapy (5.34 per 10,000 patient-years).",
"   </p>",
"   <p>",
"    Reported deaths due to statin-induced rhabdomyolysis have averaged 0.15 per million prescriptions dispensed in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/108\">",
"     108",
"    </a>",
"    ]. This risk is greater with cerivastatin, which was withdrawn from the market in August 2001 after reports of 31 deaths from rhabdomyolysis, most often in older patients who were also taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/108\">",
"     108",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Muscle biopsy obtained early in the course of rhabdomyolysis shows myonecrosis without vasculitis or significant inflammation. Biopsy later in the course may show some mononuclear cell infiltration suggestive of an inflammatory repair process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/76,103,104\">",
"     76,103,104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Asymptomatic myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible existence of asymptomatic myopathy was evaluated in a study that examined muscle biopsies obtained during vascular surgery from patients without muscle symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/109\">",
"     109",
"    </a>",
"    ]. Morphological analysis by an investigator blinded to treatment status found compromise of the structural integrity of muscle fibers in 10 of 14 patients treated with statins and in 1 of 8 control patients.",
"   </p>",
"   <p>",
"    Most of the 14 patients were receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    , but both patients in the study who were receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    also had damaged fibers. This observation suggests that even asymptomatic patients receiving statins may show some degree of muscle pathology on biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H262593031\">",
"    <span class=\"h2\">",
"     Neuromuscular disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;A growing number of reports have found associations between statin therapy and a variety of neuromuscular disorders, which include the idiopathic inflammatory myopathies (eg, polymyositis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/110,111\">",
"     110,111",
"    </a>",
"    ], dermatomyositis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/112-116\">",
"     112-116",
"    </a>",
"    ], and inclusion body myositis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/117\">",
"     117",
"    </a>",
"    ]) in a time frame consistent with a toxic effect. While these reports demonstrated distinct inflammatory infiltrates on muscle biopsy, an immune myopathy may develop manifesting MHC-1 upregulation without inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/118\">",
"     118",
"    </a>",
"    ]. This histologically-distinct noninflammatory statin myopathy, referred to as necrotizing myopathy, is characterized by a macrophagocytic infiltrate engulfing necrotic muscle fibers, responds to immune therapy, and is presumably autoimmune [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/119-121\">",
"     119-121",
"    </a>",
"    ]. Autoantibodies directed against HMG CoA reductase have been detected in patients with statin-associated necrotizing myopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/122\">",
"     122",
"    </a>",
"    ]. Necrotizing myopathies can be idiopathic, paraneoplastic, or associated with a connective-tissue disorder and can develop after statin discontinuation.",
"   </p>",
"   <p>",
"    Other disorders that may have been induced by statin therapy include mononeuritis multiplex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/123\">",
"     123",
"    </a>",
"    ], malignant hyperthermia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/124,125\">",
"     124,125",
"    </a>",
"    ], and statin-induced extraocular muscle myopathy mimicking Graves&rsquo; ophthalmopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/126\">",
"     126",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the increased risk of myopathy associated with statin therapy, routine monitoring of serum creatine kinase (CK) levels is not recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/102,127,128\">",
"     102,127,128",
"    </a>",
"    ]. However, it is useful to obtain a baseline serum CK before initiation of statin therapy for reference in case symptoms develop.",
"   </p>",
"   <p>",
"    There are important differences in serum CK levels among racial groups; as an example, high concentrations of CK are observed in blacks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/129,130\">",
"     129,130",
"    </a>",
"    ]. Additionally, many standard normal ranges on assays of CK appear to have an inappropriately low \"upper limit of normal\" even for non&ndash;black populations (",
"    <a class=\"graphic graphic_table graphicRef70806 \" href=\"mobipreview.htm?36/47/37629\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/131\">",
"     131",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients treated with statins should be alerted to report the new onset of myalgias or weakness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H301173463\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with significant muscle toxicity from a statin should discontinue therapy. Based on clinical experience, in the absence of clinical symptoms, a creatine kinase (CK) level &gt;10 times the upper limit of normal that is felt to be due to a statin is an indication for discontinuing the medication. Patients should drink large quantities of fluids to facilitate renal excretion of myoglobin.",
"   </p>",
"   <p>",
"    If a patient requires a statin and experiences muscle toxicity (other than rhabdomyolysis) while on a statin other than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    , once symptoms have resolved and the CK has returned to baseline off statin therapy, it is reasonable to try pravastatin or fluvastatin with careful monitoring.",
"   </p>",
"   <p>",
"    If this is unsuccessful, options include alternate-day dosing or a trial of Coenzyme Q10",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vitamin D in patients with vitamin D deficiency.",
"   </p>",
"   <p>",
"    Patients with a history of statin-induced rhabdomyolysis should generally not be treated with another statin (including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    ), because of the risk of recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/92\">",
"     92",
"    </a>",
"    ]. In some cases, it may be reasonable to retry statin therapy after the resolution of an acute reversible event that contributed to muscle toxicity (eg, undetected hypothyroidism, acute renal failure, biliary obstruction, use of other medications that increase statin levels).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H301173471\">",
"    <span class=\"h2\">",
"     Switching statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    appear to have much less intrinsic muscle toxicity than other statins (see",
"    <a class=\"local\" href=\"#H107312612\">",
"     'Statin characteristics'",
"    </a>",
"    above). Thus, in patients who have developed statin myopathy (other than rhabdomyolysis) on a statin other than pravastatin or fluvastatin, the first option is to switch to one of those two medications once symptoms have resolved off statin therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Switching to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    was studied in a randomized trial in 199 patients with prior statin myopathy; 17 percent of patients treated with fluvastatin monotherapy developed recurrent muscle symptoms (versus 24 percent with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    and 14 percent with combination therapy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Coenzyme Q10",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is only limited evidence for benefit, if a patient requires a statin and experiences muscle pain while on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    (the two statins felt to have the lowest risk of myopathy), we suggest a trial of supplementation with CoQ10 at a dose of 150 to 200 mg daily prior to rechallenge and during the course of statin therapy.",
"   </p>",
"   <p>",
"    As discussed above, CoQ10 depletion may play a role in statin myopathy (see",
"    <a class=\"local\" href=\"#H107312583\">",
"     'Pathogenesis'",
"    </a>",
"    above). There is little published evidence of benefit of CoQ10 for the treatment of myopathy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A small 30-day randomized trial that compared CoQ10 100 mg daily with vitamin E 400 IU daily in 32 patients with myopathic pain while receiving statins found a significant reduction in pain in patients treated with CoQ10, but not in patients treated with vitamin E; neither treatment affected plasma CK levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/133\">",
"       133",
"      </a>",
"      ]. Short-term administration of CoQ10 would not be expected to substantially increase tissue levels of ubiquinone, and the findings from this trial need confirmation in a larger trial with a longer duration of CoQ10 therapy.",
"     </li>",
"     <li>",
"      A small randomized trial compared 12 weeks of CoQ10 200 mg daily with placebo in 44 patients with statin-induced myalgia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/134\">",
"       134",
"      </a>",
"      ]. Patients were off lipid-lowering therapy for two weeks prior to randomization and were then treated with escalating doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      (10 to 40 mg daily as tolerated). CoQ10 supplementation increased plasma CoQ10 levels but reportedly did not increase the proportion of patients who tolerated simvastatin or decrease myalgia scores.",
"     </li>",
"     <li>",
"      A small randomized trial in patients with recent-onset myalgias after initiation or dose increase of statin therapy found no benefit of CoQ10 60 mg twice daily compared with placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/135\">",
"       135",
"      </a>",
"      ]. Patients with a CK level above 300",
"      <span class=\"nowrap\">",
"       U/L",
"      </span>",
"      were excluded from the trial.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21625087\">",
"    <span class=\"h2\">",
"     Vitamin D",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a patient with statin myopathy is known to be vitamin D deficient, it is reasonable to administer vitamin D replacement therapy and then rechallenge with statin therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment of vitamin D deficiency in adults\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some studies, but not all, have suggested that low vitamin D levels may be associated with statin myopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/136\">",
"     136",
"    </a>",
"    ]. Case reports, case series, and some small, inadequately controlled studies have reported improvement in symptoms of statin myopathy in patients supplemented with vitamin D [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/136,137\">",
"     136,137",
"    </a>",
"    ]. Even if patients with vitamin D deficiency have a higher rate of statin myopathy, vitamin D may be a marker for other risk factors for myopathy (such as other nutritional deficiencies) rather than itself the cause of myopathy.",
"   </p>",
"   <p>",
"    While awaiting better evidence, we do not suggest obtaining vitamin D levels simply because a patient has statin myopathy. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H262665596\">",
"    <span class=\"h2\">",
"     Alternate-day dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Daily dosing of statins is preferred whenever possible, since daily regimens are the ones that have been studied and proven to reduce clinical events. Clinical experience suggests that alternate-day dosing may improve the tolerability of statins in patients experiencing myalgias, and this strategy can reasonably be tried in patients unable to tolerate daily statin therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32314?source=see_link&amp;anchor=H22#H22\">",
"     \"Statins: Actions, side effects, and administration\", section on 'Alternative dosing regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H301173455\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H301173654\">",
"    <span class=\"h2\">",
"     Choice of statin",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    appear to have much less intrinsic muscle toxicity than other statins (see",
"    <a class=\"local\" href=\"#H107312612\">",
"     'Statin characteristics'",
"    </a>",
"    above). Both these agents are relatively lower potency statins; however, whenever they are adequate for the clinical situation, we suggest treating with one or the other to reduce the risk of statin myopathy.",
"   </p>",
"   <p>",
"    As discussed below, the choice of statin is also important in dealing with potential drug interactions. (See",
"    <a class=\"local\" href=\"#H301173662\">",
"     'Drug interactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H301173662\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain drug interactions are discussed below. Additional detail about specific statin interactions and management suggestions for avoiding elevated myopathy risk is available by using the Lexi-Interact program included with UpToDate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H301173724\">",
"    <span class=\"h3\">",
"     CYP3A4 drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, the risk of muscle injury is a substantially increased when taking the combination of statins extensively metabolized by cytochrome P450 3A4 (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    ) and drugs that inhibit CYP3A4 (",
"    <a class=\"graphic graphic_table graphicRef76992 \" href=\"mobipreview.htm?9/45/9950\">",
"     table 1",
"    </a>",
"    ) (see",
"    <a class=\"local\" href=\"#H107312713\">",
"     'Concurrent drug therapy'",
"    </a>",
"    above).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     Pravastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/56/9095?source=see_link\">",
"     pitavastatin",
"    </a>",
"    are preferred when concurrent therapy with a strong inhibitor of CYP3A4 cannot be avoided.",
"   </p>",
"   <p>",
"    The importance of using a statin that is not extensively metabolized by CYP3A4 when administering a CYP3A4 inhibitor is illustrated by the moderate CYP3A4 inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . Regular-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    (40 to 80",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    are associated with an appreciable risk of myositis (as high as 13 to 30 percent) in cyclosporine-treated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. Lovastatin levels much higher than the therapeutic range have been noted in patients with rhabdomyolysis who were treated with cyclosporine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/55\">",
"     55",
"    </a>",
"    ]. Although the data are limited, myositis has also been described when cyclosporine is given with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    , which is metabolized by CYP3A4 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. In contrast,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    , which are not extensively metabolized by CYP3A4, do not appear to increase the risk of myopathy when given concurrently with cyclosporine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/56,138-140\">",
"     56,138-140",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The safety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    in such patients was illustrated in an open-label study that compared pravastatin (40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    in 87 cardiac transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/56\">",
"     56",
"    </a>",
"    ]. Rhabdomyolysis or myositis occurred only with simvastatin therapy (13.3 percent). A similar lack of muscle toxicity was noted in a placebo-controlled trial in which none of 50 cardiac transplant recipients treated with pravastatin (40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    developed myalgia or myositis during one year of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/138\">",
"     138",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The safety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    (20 and 40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    taken with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in hypercholesterolemic renal transplant patients has been demonstrated in several small trials; mean serum trough levels of cyclosporine were not significantly altered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/75,141,142\">",
"     75,141,142",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/56/9095?source=see_link\">",
"     pitavastatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    are not metabolized by CYP3A4, manufacturers&rsquo; pharmacokinetic data show they can interact with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , apparently by a non-CYP mechanism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/68,74\">",
"     68,74",
"    </a>",
"    ]. Hepatic uptake of pitavastatin and rosuvastatin is regulated by hepatocyte membrane transporters, known as organic anion transport proteins (OATPs), whose effects can be inhibited by certain drugs (ie, cyclosporine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ) causing increased levels of pitavastatin or rosuvastatin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/143,144\">",
"     143,144",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H301173732\">",
"    <span class=\"h3\">",
"     Fibrates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    are at increased risk for muscle toxicity. Options include choosing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    when treating with gemfibrozil or treating with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    rather than gemfibrozil; fenofibrate is the preferred fibrate in patients who require combined therapy with a statin and fibrate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/145\">",
"     145",
"    </a>",
"    ]. Combination therapy with gemfibrozil and even pravastatin or fluvastatin should be used cautiously and only if the benefit is likely to outweigh the low risk of muscle toxicity.",
"   </p>",
"   <p>",
"    An increased risk of muscle toxicity, as high as 1 to 5 percent, has been described with the administration of some statins (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    ) with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/55,76-78\">",
"     55,76-78",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     Pravastatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    appear to have little muscle toxicity when used in combination with gemfibrozil [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/146-149\">",
"     146-149",
"    </a>",
"    ], despite the observation that gemfibrozil increases plasma concentrations of pravastatin twofold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/150\">",
"     150",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential importance of the type of statin was evaluated in a study that examined claims data from 11 managed care plans, which included 252,460 patients treated with lipid lowering agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/13\">",
"     13",
"    </a>",
"    ]. The average incidence of hospitalization for rhabdomyolysis was 5.98 per 10,000 patient-years (95% CI 0.72-216.0) for patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    in combination with a fibrate. The incidence of hospitalization was approximately 10-fold higher with combination fibrates and statins than with statin monotherapy. Although the study did not find a statistical difference in the incidence of rhabdomyolysis among these three statins, no cases of rhabdomyolysis were seen with pravastatin.",
"   </p>",
"   <p>",
"    Toxicity can also be minimized by using other statins in relatively low doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/148,151,152\">",
"     148,151,152",
"    </a>",
"    ]. This was illustrated in a trial of 389 patients with refractory familial combined hyperlipidemia who were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    plus either gemfibrozil or ciprofibrate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/148\">",
"     148",
"    </a>",
"    ]. After a mean follow-up of 29 months, no patient developed myopathy or rhabdomyolysis.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/23/17784?source=see_link\">",
"     Fenofibrate",
"    </a>",
"    appears to be safer than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    when used with statins. Glucuronidation, which is an important pathway for renal excretion of lipophilic statins, appears to be significantly inhibited by gemfibrozil but not fenofibrate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/153,154\">",
"     153,154",
"    </a>",
"    ]. In clinical studies, serum levels of statins increase 1.9- to 5.7-fold in gemfibrozil-treated subjects but are unchanged in fenofibrate-treated subjects.",
"   </p>",
"   <p>",
"    In the randomized, placebo-controlled FIELD trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    in almost 10,000 patients with type 2 diabetes, there was a low incidence of myopathy (less than 1 percent) that was not different from placebo, whether or not patients were also taking a statin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/155\">",
"     155",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7754121\">",
"    <span class=\"h3\">",
"     Niacin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the absolute increase in risk appears to be small, niacin seems to increase the risk of myopathy in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    , and perhaps other statins (see",
"    <a class=\"local\" href=\"#H107312713\">",
"     'Concurrent drug therapy'",
"    </a>",
"    above). This increased risk may be a particular concern in patients from China (see",
"    <a class=\"local\" href=\"#H107312686\">",
"     'Patient characteristics'",
"    </a>",
"    above), and we suggest avoiding the combination of simvastatin and niacin in Chinese patients and only using niacin with caution in patients receiving other statins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H301173755\">",
"    <span class=\"h3\">",
"     Dose limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manufacturer recommendations for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    , and also for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    , state that the medications are contraindicated in patients treated with most strong CYP3A4 inhibitors (",
"    <a class=\"graphic graphic_table graphicRef76992 \" href=\"mobipreview.htm?9/45/9950\">",
"     table 1",
"    </a>",
"    ) and that there are dose limitations or recommendations to avoid these statins when used in conjunction with a number of other medications, including limiting simvastatin to 20 mg daily when taken with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/43,65\">",
"     43,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given high rates of myopathy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    80 mg daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/156\">",
"     156",
"    </a>",
"    ], and the availability of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    and generic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    , we suggest not treating patients with doses of simvastatin above 40",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    Additionally, clinicians should strongly consider switching even patients who are currently tolerating simvastatin 80",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    to one of these other statin options. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32314?source=see_link&amp;anchor=H5#H5\">",
"     \"Statins: Actions, side effects, and administration\", section on 'Potency'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For more detailed information about dose limitations, refer to the individual Lexicomp drug monographs included with UpToDate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H301173647\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some clinicians recommend that patients taking statins take CoQ10 to try to prevent myopathy. Although there is anecdotal evidence for benefit, there are no published controlled trials or even moderate-size case series. A few case reports have noted benefit with doses of 30 to 250 mg daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/157\">",
"     157",
"    </a>",
"    ]. There is currently inadequate evidence to recommend CoQ10 supplementation for",
"    <strong>",
"     prevention",
"    </strong>",
"    of statin-induced muscle toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/0/33802/abstract/158\">",
"     158",
"    </a>",
"    ]. We do feel that a trial of CoQ10 in patients who have",
"    <strong>",
"     previously developed",
"    </strong>",
"    statin myopathy may be appropriate under some circumstances. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Coenzyme Q10'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Clinical presentation and diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Muscle injury is uncommon with statin therapy alone, with a frequency of 2 to 11 percent for myalgias, 0.5 percent for myositis, and less than 0.1 percent for rhabdomyolysis. Patients can experience statin-induced myalgias without an elevation in serum creatine kinase (CK) concentration. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Myopathic syndromes associated with statin therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Muscle symptoms usually begin within weeks to months after starting statins. Myalgias, weakness, and serum CK concentrations usually return to normal over days to weeks after drug discontinuation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Time course of myopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not routinely monitoring serum CK levels in patients on statin therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). It is useful to obtain a baseline CK level for reference purposes prior to starting statin therapy. Patients treated with statins should be alerted to report the new onset of myalgias or weakness. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of symptomatic statin myopathy with laboratory abnormalities (ie, elevated serum CK) is typically straightforward and based on a temporal association for both onset with initiation of statin therapy and resolution with statin withdrawal. However, some patients can have muscle symptoms from statin therapy without an elevation in serum CK, and it can then be difficult to be certain whether muscle symptoms are due to statin therapy. (See",
"      <a class=\"local\" href=\"#H107311578\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical judgment is necessary in interpreting elevated CK levels in patients on statins. CK elevations can be related to hypothyroidism or muscle injury during sports (running, diving for a volleyball, hockey), and patients who engage in high-impact sports should be advised to have a CK measured before engaging in exercise that day. (See",
"      <a class=\"local\" href=\"#H107311578\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Prevention and management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"       Pravastatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"       fluvastatin",
"      </a>",
"      appear to have much less intrinsic muscle toxicity than other statins. Thus, in patients who have developed statin myopathy (other than rhabdomyolysis) on a statin other than pravastatin or fluvastatin, we suggest switching to one of those two medications once symptoms have resolved off statin therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H301173471\">",
"       'Switching statins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of muscle injury is a substantially increased when taking both statins extensively metabolized by cytochrome P450 3A4 (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42312?source=see_link\">",
"       lovastatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      ) and drugs that interfere with CYP3A4 (",
"      <a class=\"graphic graphic_table graphicRef76992 \" href=\"mobipreview.htm?9/45/9950\">",
"       table 1",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"       Pravastatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"       fluvastatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"       rosuvastatin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/56/9095?source=see_link\">",
"       pitavastatin",
"      </a>",
"      are preferred when concurrent therapy with a strong inhibitor of CYP3A4 cannot be avoided. (See",
"      <a class=\"local\" href=\"#H301173724\">",
"       'CYP3A4 drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Grapefruit juice inhibits CYP3A4; however, daily consumption of eight ounces or less of grapefruit juice, or one-half of a grapefruit or less, is unlikely to increase the risk of an adverse interaction or muscle injury. (See",
"      <a class=\"local\" href=\"#H107312713\">",
"       'Concurrent drug therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Enhanced susceptibility to statin-associated myopathy occurs in patients with acute or chronic renal failure, obstructive liver disease, and hypothyroidism. (See",
"      <a class=\"local\" href=\"#H107312686\">",
"       'Patient characteristics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who are being treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"       gemfibrozil",
"      </a>",
"      and require a statin, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"       fluvastatin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, in patients who require combined therapy with a statin (including pravastatin or fluvastatin) and a fibrate, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/23/17784?source=see_link\">",
"       fenofibrate",
"      </a>",
"      rather than gemfibrozil (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H301173732\">",
"       'Fibrates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although there is only limited evidence for benefit, if a patient requires a statin and experiences muscle pain while on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"       fluvastatin",
"      </a>",
"      , we suggest a trial of supplementation with CoQ10 (at a dose of 150 mg to 200 mg daily) prior to rechallenge and during the course of statin therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Coenzyme Q10'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who are unable to tolerate daily dosing of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"       fluvastatin",
"      </a>",
"      , we suggest a trial of alternate-day dosing of statin therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H262665596\">",
"       'Alternate-day dosing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/1\">",
"      Grundy SM. Can statins cause chronic low-grade myopathy? Ann Intern Med 2002; 137:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/2\">",
"      Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol 1993; 33:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/3\">",
"      Rundek T, Naini A, Sacco R, et al. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol 2004; 61:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/4\">",
"      P&auml;iv&auml; H, Thelen KM, Van Coster R, et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 2005; 78:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/5\">",
"      Bleske BE, Willis RA, Anthony M, et al. The effect of pravastatin and atorvastatin on coenzyme Q10. Am Heart J 2001; 142:E2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/6\">",
"      Laaksonen R, Jokelainen K, Laakso J, et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 1996; 77:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/7\">",
"      Lamperti C, Naini AB, Lucchini V, et al. Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol 2005; 62:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/8\">",
"      Larsen S, Stride N, Hey-Mogensen M, et al. Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance. J Am Coll Cardiol 2013; 61:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/9\">",
"      Phillips PS, Ciaraldi TP, Kim DL, et al. Myotoxic reactions to lipid-lowering therapy are associated with altered oxidation of fatty acids. Endocrine 2009; 35:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/10\">",
"      Iacobazzi V, Convertini P, Infantino V, et al. Statins, fibrates and retinoic acid upregulate mitochondrial acylcarnitine carrier gene expression. Biochem Biophys Res Commun 2009; 388:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/11\">",
"      Hanai J, Cao P, Tanksale P, et al. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest 2007; 117:3940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/12\">",
"      \"The Pink Sheet\" FDC Reports. 2002; 64(vol 23):5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/13\">",
"      Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292:2585.",
"     </a>",
"    </li>",
"    <li>",
"     Physicians' Desk Reference, Medical Economics, Montvale, NJ 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/15\">",
"      Pfeffer MA, Keech A, Sacks FM, et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation 2002; 105:2341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/16\">",
"      Gadbut AP, Caruso AP, Galper JB. Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin. J Mol Cell Cardiol 1995; 27:2397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/17\">",
"      Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/18\">",
"      \"The Pink Sheet\" FDC Reports. Chevy Chase, MD. 2004; 66:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/19\">",
"      Zinman L, Sadeghi R, Gawel M, et al. Are statin medications safe in patients with ALS? Amyotroph Lateral Scler 2008; 9:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/20\">",
"      Dupuis L, Corcia P, Fergani A, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 2008; 70:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/21\">",
"      Dupuis L, Oudart H, Ren&eacute; F, et al. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proc Natl Acad Sci U S A 2004; 101:11159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/22\">",
"      Robichon C, Dugail I. De novo cholesterol synthesis at the crossroads of adaptive response to extracellular stress through SREBP. Biochimie 2007; 89:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/23\">",
"      Parmar B, Francis PJ, Ragge NK. Statins, fibrates, and ocular myasthenia. Lancet 2002; 360:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/24\">",
"      Cartwright MS, Jeffery DR, Nuss GR, Donofrio PD. Statin-associated exacerbation of myasthenia gravis. Neurology 2004; 63:2188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/25\">",
"      Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002; 137:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/26\">",
"      Chariot P, Abadia R, Agnus D, et al. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am J Med 1993; 94:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/27\">",
"      Tsivgoulis G, Spengos K, Karandreas N, et al. Presymptomatic neuromuscular disorders disclosed following statin treatment. Arch Intern Med 2006; 166:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/28\">",
"      Livingstone C, Al Riyami S, Wilkins P, Ferns GA. McArdle's disease diagnosed following statin-induced myositis. Ann Clin Biochem 2004; 41:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/29\">",
"      Baker SK, Vladutiu GD, Tarnopolsky MA. McArdle disease unmasked by statin exposure. Muscle Nerve 2003; (Suppl 12):S73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/30\">",
"      Voermans NC, Lammens M, Wevers RA, et al. Statin-disclosed acid maltase deficiency. J Intern Med 2005; 258:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/31\">",
"      Echaniz-Laguna A, Mohr M, Tranchant C. Neuromuscular symptoms and elevated creatine kinase after statin withdrawal. N Engl J Med 2010; 362:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/32\">",
"      Delgado-L&oacute;pez F, Bautista-Lorite J, Villamil-Fern&aacute;ndez F. [Worsening for using statin in carnitine palmityol transferase deficiency myopathy]. Rev Neurol 2004; 38:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/33\">",
"      Baker SK, Tarnopolsky MA. Sporadic rippling muscle disease unmasked by simvastatin. Muscle Nerve 2006; 34:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/34\">",
"      Knoblauch H, Schoewel V, Kress W, et al. Another side to statin-related side effects. Ann Intern Med 2010; 152:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/35\">",
"      Supala-Berger A, Fine E, Heffner R, Young-McLain E. Hyaline inclusion myopathy: unmasked by statin therapy. Muscle Nerve 2009; 40:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/36\">",
"      Evangelista T, Ferro J, Pereira P, de Carvalho M. A case of asymptomatic cytoplasmic body myopathy revealed by sinvastatin. Neuromuscul Disord 2009; 19:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/37\">",
"      al-Jubouri MA, Briston PG, Sinclair D, et al. Myxoedema revealed by simvastatin induced myopathy. BMJ 1994; 308:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/38\">",
"      Scalvini T, Marocolo D, Cerudelli B, et al. Pravastatin-associated myopathy. Report of a case. Recenti Prog Med 1995; 86:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/39\">",
"      Vladutiu GD. Genetic predisposition to statin myopathy. Curr Opin Rheumatol 2008; 20:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/40\">",
"      SEARCH Collaborative Group, Link E, Parish S, et al. SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med 2008; 359:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/41\">",
"      Voora D, Shah SH, Spasojevic I, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009; 54:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/42\">",
"      Knauer MJ, Urquhart BL, Meyer zu Schwabedissen HE, et al. Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res 2010; 106:297.",
"     </a>",
"    </li>",
"    <li>",
"     www.merck.com/product/usa/pi_circulars/z/zocor/zocor_pi.pdf (Accessed on December 19, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/44\">",
"      HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/45\">",
"      Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006; 114:2788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/46\">",
"      Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine (Baltimore) 2005; 84:377.",
"     </a>",
"    </li>",
"    <li>",
"     Craig Williams. Myopathy. In: Drug-Induced Diseases Prevention, Detection and Management, 2nd edition, James E. Tisdale, Douglas A. Miller.  (Eds), American Society of Health-System Pharmacists, Inc., Bethesda 2010. p.1017.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/48\">",
"      Reaven P, Witztum JL. Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med 1988; 109:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/49\">",
"      Guyton JR, Capuzzi DM. Treatment of hyperlipidemia with combined niacin-statin regimens. Am J Cardiol 1998; 82:82U.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/50\">",
"      Alsheikh-Ali AA, Karas RH. Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system). Am J Cardiol 2007; 99:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/51\">",
"      Bays H. Safety of niacin and simvastatin combination therapy. Am J Cardiol 2008; 101:3B.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/52\">",
"      Chatzizisis YS, Koskinas KC, Misirli G, et al. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf 2010; 33:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/53\">",
"      Martin J, Krum H. Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class: are they clinically relevant? Drug Saf 2003; 26:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/54\">",
"      Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988; 319:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/55\">",
"      Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988; 62:28J.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/56\">",
"      Keogh A, Macdonald P, Kaan A, et al. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant 2000; 19:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/57\">",
"      Yee HS, Fong NT. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias. Ann Pharmacother 1998; 32:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/58\">",
"      Patel DN, Pagani FD, Koelling TM, et al. Safety and efficacy of atorvastatin in heart transplant recipients. J Heart Lung Transplant 2002; 21:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/59\">",
"      Ayanian JZ, Fuchs CS, Stone RM. Lovastatin and rhabdomyolysis. Ann Intern Med 1988; 109:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/60\">",
"      Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med 1995; 333:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/61\">",
"      Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/62\">",
"      Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 2002; 16:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/63\">",
"      Baker SK, Goodwin S, Sur M, Tarnopolsky MA. Cytoskeletal myotoxicity from simvastatin and colchicine. Muscle Nerve 2004; 30:799.",
"     </a>",
"    </li>",
"    <li>",
"     Zocor (simvastatin) US prescribing information (revision 10/2012) available at NIH DailyMed website file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fdbfe194-b845-42c5-bb87-a48118bc72e7 (Accessed on March 08, 2013).",
"    </li>",
"    <li>",
"     file://www.fda.gov/Drugs/DrugSafety/ucm293101.htm (Accessed on February 28, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/66\">",
"      Penzak SR, Chuck SK. Management of protease inhibitor-associated hyperlipidemia. Am J Cardiovasc Drugs 2002; 2:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/67\">",
"      van der Lee M, Sankatsing R, Schippers E, et al. Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. Antivir Ther 2007; 12:1127.",
"     </a>",
"    </li>",
"    <li>",
"     Livalo (pitavastatin) US prescribing information. Available at NIH DailyMed website file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b3c41a2f-da77-4465-8af6-038006a7ea58 (Accessed on March 08, 2013).",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: Interactions between certain HIV or hepatitis C drugs and cholesterol-lowering statin drugs can increase the risk of muscle injury file://www.fda.gov/Drugs/DrugSafety/ucm293877.htm (Accessed on March 08, 2013).",
"    </li>",
"    <li>",
"     www.fda.gov/cder/drug/InfoSheets/HCP/simvastatin_amiodaroneHCP.htm (Accessed on August 12, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/71\">",
"      Reddy P, Ellington D, Zhu Y, et al. Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily. Br J Clin Pharmacol 2011; 72:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/72\">",
"      Holdaas H, Hagen E, Asberg A, et al. Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients. Int J Clin Pharmacol Ther 2006; 44:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/73\">",
"      Kantola T, Backman JT, Niemi M, et al. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol 2000; 56:225.",
"     </a>",
"    </li>",
"    <li>",
"     Crestor (rosuvastatin) US prescribing information (revision 12/2012) available at NIH DailyMed website: file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb0f3b5e-4bc6-41c9-66b9-6257e2513512 (Accessed on March 08, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/75\">",
"      Holdaas H, Hartmann A, Stenstr&oslash;m J, et al. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine. Am J Cardiol 1995; 76:102A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/76\">",
"      Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/77\">",
"      Glueck CJ, Oakes N, Speirs J, et al. Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias. Am J Cardiol 1992; 70:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/78\">",
"      Duell PB, Connor WE, Illingworth DR. Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am J Cardiol 1998; 81:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/79\">",
"      Alayli G, Cengiz K, Cant&uuml;rk F, et al. Acute myopathy in a patient with concomitant use of pravastatin and colchicine. Ann Pharmacother 2005; 39:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/80\">",
"      Kotanko P, Kirisits W, Skrabal F. Rhabdomyolysis and acute renal graft impairment in a patient treated with simvastatin, tacrolimus, and fusidic acid. Nephron 2002; 90:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/81\">",
"      Wenisch C, Krause R, Fladerer P, et al. Acute rhabdomyolysis after atorvastatin and fusidic acid therapy. Am J Med 2000; 109:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/82\">",
"      Yuen SL, McGarity B. Rhabdomyolysis secondary to interaction of fusidic acid and simvastatin. Med J Aust 2003; 179:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/83\">",
"      Magee CN, Medani SA, Leavey SF, et al. Severe rhabdomyolysis as a consequence of the interaction of fusidic acid and atorvastatin. Am J Kidney Dis 2010; 56:e11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/84\">",
"      O'Mahony C, Campbell VL, Al-Khayatt MS, Brull DJ. Rhabdomyolysis with atorvastatin and fusidic acid. Postgrad Med J 2008; 84:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/85\">",
"      Burtenshaw AJ, Sellors G, Downing R. Presumed interaction of fusidic acid with simvastatin. Anaesthesia 2008; 63:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/86\">",
"      Kearney S, Carr AS, McConville J, et al. Rhabdomyolysis after co-prescription of statin and fusidic acid. BMJ 2012; 345:e6562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/87\">",
"      Karas RH, Kashyap ML, Knopp RH, et al. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Am J Cardiovasc Drugs 2008; 8:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/88\">",
"      Thompson PD, Zmuda JM, Domalik LJ, et al. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism 1997; 46:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/89\">",
"      Meador BM, Huey KA. Statin-associated myopathy and its exacerbation with exercise. Muscle Nerve 2010; 42:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/90\">",
"      Coen PM, Flynn MG, Markofski MM, et al. Adding exercise training to rosuvastatin treatment: influence on serum lipids and biomarkers of muscle and liver damage. Metabolism 2009; 58:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/91\">",
"      Kearns AK, Bilbie CL, Clarkson PM, et al. The creatine kinase response to eccentric exercise with atorvastatin 10 mg or 80 mg. Atherosclerosis 2008; 200:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/92\">",
"      Antons KA, Williams CD, Baker SK, Phillips PS. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 2006; 119:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/93\">",
"      Thompson PD, Clarkson PM, Rosenson RS, National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel. An assessment of statin safety by muscle experts. Am J Cardiol 2006; 97:69C.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/94\">",
"      Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/95\">",
"      Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med 2009; 150:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/96\">",
"      Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 2005; 165:2671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/97\">",
"      Dujovne CA, Chremos AN, Pool JL, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin. Am J Med 1991; 91:25S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/98\">",
"      Boccuzzi SJ, Bocanegra TS, Walker JF, et al. Long-term safety and efficacy profile of simvastatin. Am J Cardiol 1991; 68:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/99\">",
"      Pedersen TR, Berg K, Cook TJ, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1996; 156:2085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/100\">",
"      Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. Circulation 2013; 127:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/101\">",
"      Sathasivam S, Lecky B. Statin induced myopathy. BMJ 2008; 337:a2286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/102\">",
"      Smith CC, Bernstein LI, Davis RB, et al. Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting. Arch Intern Med 2003; 163:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/103\">",
"      Norman DJ, Illingworth DR, Munson J, Hosenpud J. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. N Engl J Med 1988; 318:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/104\">",
"      East C, Alivizatos PA, Grundy SM, et al. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 1988; 318:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/105\">",
"      Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003; 163:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/106\">",
"      Kiernan TJ, Rochford M, McDermott JH. Simvastatin induced rhabdomyolysis and an important clinical link with hypothyroidism. Int J Cardiol 2007; 119:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/107\">",
"      Gupta S, Blaivas M, Ike RW, Crofford LJ. Polymyositis evolving after rhabdomyolysis associated with HMG-CoA reductase inhibitors: a report of two cases. J Clin Rheumatol 2001; 7:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/108\">",
"      Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002; 346:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/109\">",
"      Draeger A, Monastyrskaya K, Mohaupt M, et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol 2006; 210:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/110\">",
"      Giordano N, Senesi M, Mattii G, et al. Polymyositis associated with simvastatin. Lancet 1997; 349:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/111\">",
"      Goldman JA, Fishman AB, Lee JE, Johnson RJ. The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis. Arthritis Rheum 1989; 32:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/112\">",
"      Vasconcelos OM, Campbell WW. Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake. Muscle Nerve 2004; 30:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/113\">",
"      No&euml;l B, Cerottini JP, Panizzon RG. Atorvastatin-induced dermatomyositis. Am J Med 2001; 110:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/114\">",
"      Khattak FH, Morris IM, Branford WA. Simvastatin-associated dermatomyositis. Br J Rheumatol 1994; 33:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/115\">",
"      Hill C, Zeitz C, Kirkham B. Dermatomyositis with lung involvement in a patient treated with simvastatin. Aust N Z J Med 1995; 25:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/116\">",
"      Rodriguez-Garcia JL, Serrano Commino M. Lovastatin-associated dermatomyositis. Postgrad Med J 1996; 72:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/117\">",
"      Huynh T, Cordato D, Yang F, et al. HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions. Intern Med J 2002; 32:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/118\">",
"      Needham M, Fabian V, Knezevic W, et al. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord 2007; 17:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/119\">",
"      Grable-Esposito P, Katzberg HD, Greenberg SA, et al. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010; 41:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/120\">",
"      Christopher-Stine L, Casciola-Rosen LA, Hong G, et al. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010; 62:2757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/121\">",
"      David WS, Chad DA, Kambadakone A, Hedley-Whyte ET. Case records of the Massachusetts General Hospital. Case 7-2012. A 79-year-old man with pain and weakness in the legs. N Engl J Med 2012; 366:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/122\">",
"      Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011; 63:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/123\">",
"      Haroon M, Devlin J. A case of ANCA-associated systemic vasculitis induced by atorvastatin. Clin Rheumatol 2008; 27 Suppl 2:S75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/124\">",
"      Krivosic-Horber R, D&eacute;pret T, Wagner JM, Maurage CA. Malignant hyperthermia susceptibility revealed by increased serum creatine kinase concentrations during statin treatment. Eur J Anaesthesiol 2004; 21:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/125\">",
"      Guis S, Bendahan D, Kozak-Ribbens G, et al. Rhabdomyolysis and myalgia associated with anticholesterolemic treatment as potential signs of malignant hyperthermia susceptibility. Arthritis Rheum 2003; 49:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/126\">",
"      Ruchala M, Szczepanek E, Puszczewicz M, et al. Not a graves' situation. Am J Med 2011; 124:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/127\">",
"      Weismantel D, Danis P. Clinical inquiries. What laboratory monitoring is appropriate to detect adverse drug reactions in patients on cholesterol-lowering agents? J Fam Pract 2001; 50:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/128\">",
"      Gotto AM Jr. Safety and statin therapy: reconsidering the risks and benefits. Arch Intern Med 2003; 163:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/129\">",
"      Black HR, Quallich H, Gareleck CB. Racial differences in serum creatine kinase levels. Am J Med 1986; 81:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/130\">",
"      Neal RC, Ferdinand KC, Ycas J, Miller E. Relationship of ethnic origin, gender, and age to blood creatine kinase levels. Am J Med 2009; 122:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/131\">",
"      Brewster LM, Mairuhu G, Sturk A, van Montfrans GA. Distribution of creatine kinase in the general population: implications for statin therapy. Am Heart J 2007; 154:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/132\">",
"      Stein EA, Ballantyne CM, Windler E, et al. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am J Cardiol 2008; 101:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/133\">",
"      Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007; 99:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/134\">",
"      Young JM, Florkowski CM, Molyneux SL, et al. Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. Am J Cardiol 2007; 100:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/135\">",
"      Bookstaver DA, Burkhalter NA, Hatzigeorgiou C. Effect of coenzyme Q10 supplementation on statin-induced myalgias. Am J Cardiol 2012; 110:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/136\">",
"      Gupta A, Thompson PD. The relationship of vitamin D deficiency to statin myopathy. Atherosclerosis 2011; 215:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/137\">",
"      Ahmed W, Khan N, Glueck CJ, et al. Low serum 25 (OH) vitamin D levels (&lt;32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res 2009; 153:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/138\">",
"      Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/139\">",
"      Yoshimura N, Oka T, Okamoto M, Ohmori Y. The effects of pravastatin on hyperlipidemia in renal transplant recipients. Transplantation 1992; 53:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/140\">",
"      Schrama YC, Hen&eacute; RJ, de Jonge N, et al. Efficacy and muscle safety of fluvastatin in cyclosporine-treated cardiac and renal transplant recipients: an exercise provocation test. Transplantation 1998; 66:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/141\">",
"      Li PK, Mak TW, Chan TH, et al. Effect of fluvastatin on lipoprotein profiles in treating renal transplant recipients with dyslipoproteinemia. Transplantation 1995; 60:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/142\">",
"      Goldberg RB, Roth D. A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine. Am J Cardiol 1995; 76:107A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/143\">",
"      Shitara Y, Maeda K, Ikejiri K, et al. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm Drug Dispos 2013; 34:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/144\">",
"      Duggan ST. Pitavastatin: a review of its use in the management of hypercholesterolaemia or mixed dyslipidaemia. Drugs 2012; 72:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/145\">",
"      Rosenson RS. Current overview of statin-induced myopathy. Am J Med 2004; 116:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/146\">",
"      Wiklund O, Angelin B, Bergman M, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 1993; 94:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/147\">",
"      Rosenson RS, Frauenheim WA. Safety of combined pravastatin-gemfibrozil therapy. Am J Cardiol 1994; 74:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/148\">",
"      Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol 1997; 80:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/149\">",
"      Farnier M, Dejager S. Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group. Am J Cardiol 2000; 85:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/150\">",
"      Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther 2003; 73:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/151\">",
"      Ellen RL, McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol 1998; 81:60B.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/152\">",
"      Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety. Eur Heart J 1995; 16:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/153\">",
"      Ballantyne CM, Davidson MH. Possible differences between fibrates in pharmacokinetic interactions with statins. Arch Intern Med 2003; 163:2394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/154\">",
"      Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002; 301:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/155\">",
"      Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366:1849.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/Drugs/DrugSafety/ucm256581.htm (Accessed on March 15, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/157\">",
"      Koumis T, Nathan JP, Rosenberg JM, Cicero LA. Strategies for the prevention and treatment of statin-induced myopathy: is there a role for ubiquinone supplementation? Am J Health Syst Pharm 2004; 61:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/0/33802/abstract/158\">",
"      Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007; 49:2231.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6833 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-202.43.93.2-77D3A94D3A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_0_33802=[""].join("\n");
var outline_f33_0_33802=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H107312583\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H107312605\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H107312612\">",
"      Statin characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H107312679\">",
"      Pre-existing neuromuscular disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H107314231\">",
"      Hypothyroidism and other disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H107312686\">",
"      Patient characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H107312713\">",
"      Concurrent drug therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H107312769\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MYOPATHIC SYNDROMES ASSOCIATED WITH STATIN THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Time course of myopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Myalgias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H107311521\">",
"      - Incidence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H107311528\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H107311578\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Myositis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Asymptomatic myopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H262593031\">",
"      Neuromuscular disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H301173463\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H301173471\">",
"      Switching statins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Coenzyme Q10",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21625087\">",
"      Vitamin D",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H262665596\">",
"      Alternate-day dosing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H301173455\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H301173654\">",
"      Choice of statin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H301173662\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H301173724\">",
"      - CYP3A4 drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H301173732\">",
"      - Fibrates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7754121\">",
"      - Niacin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H301173755\">",
"      - Dose limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H301173647\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Clinical presentation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Prevention and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6833\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6833|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/45/9950\" title=\"table 1\">",
"      Inhibitors and inducers of cytochrome P450 3A4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/23/33147\" title=\"table 2\">",
"      Defin statin-related issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/47/37629\" title=\"table 3\">",
"      Distribution serum CK",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/23/2424?source=related_link\">",
"      Approach to the patient with myalgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27722?source=related_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8056?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromyalgia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35608?source=related_link\">",
"      Differential diagnosis of fibromyalgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/26/29093?source=related_link\">",
"      Hypothyroid myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/56/36745?source=related_link\">",
"      Muscle enzymes in the evaluation of neuromuscular diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42472?source=related_link\">",
"      Overview of soft tissue rheumatic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21847?source=related_link\">",
"      Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32314?source=related_link\">",
"      Statins: Actions, side effects, and administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in primary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_0_33803="Fracture stages of healing";
var content_f33_0_33803=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50629&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50629&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Fractures: Stages of healing",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Stage of healing",
"      </td>",
"      <td class=\"subtitle1\">",
"       Early",
"      </td>",
"      <td class=\"subtitle1\">",
"       Peak",
"      </td>",
"      <td class=\"subtitle1\">",
"       Late",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Resolution of soft-tissue swelling",
"      </td>",
"      <td>",
"       2 to 5 days",
"      </td>",
"      <td>",
"       4 to 10 days",
"      </td>",
"      <td>",
"       10 to 21 days",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Periosteal new bone",
"      </td>",
"      <td>",
"       4 to 10 days",
"      </td>",
"      <td>",
"       10 to 14 days",
"      </td>",
"      <td>",
"       14 to 21 days",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Loss of fracture line definition",
"      </td>",
"      <td>",
"       10 to 14 days",
"      </td>",
"      <td>",
"       14 to 21 days",
"      </td>",
"      <td>",
"       ---",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Soft callus*",
"      </td>",
"      <td>",
"       7 to 14 days",
"      </td>",
"      <td>",
"       14 to 21 days",
"      </td>",
"      <td>",
"       ---",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hard callus*",
"      </td>",
"      <td>",
"       14 to 21 days",
"      </td>",
"      <td>",
"       21 to 42 days",
"      </td>",
"      <td>",
"       42 to 90 days",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Remodeling",
"      </td>",
"      <td>",
"       3 months",
"      </td>",
"      <td>",
"       1 year",
"      </td>",
"      <td>",
"       2 years to epiphyseal closure",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The difference between soft and hard callus is that hard callus bridges the fracture site so that the fracture line begins to fill in.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Kocher, MS, Kasser, JR. J Am Acad Orthop Surg 2000; 8:10; and Morzaria, S, Walton, JM, MacMillan, A. J Pediatr Surg 1998; 33:871.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_0_33803=[""].join("\n");
var outline_f33_0_33803=null;
var title_f33_0_33804="Available rabies biologics";
var content_f33_0_33804=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F51563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F51563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Currently available rabies biologics - United States, 2008",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Human rabies vaccine",
"       </td>",
"       <td class=\"subtitle1\">",
"        Product name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Manufacturer",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Indications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Human diploid cell vaccine",
"       </td>",
"       <td rowspan=\"3\">",
"        Imovax&reg; Rabies*",
"       </td>",
"       <td>",
"        sanofi Pasteur",
"       </td>",
"       <td rowspan=\"3\">",
"        1 mL",
"       </td>",
"       <td rowspan=\"3\">",
"        Intramuscular",
"       </td>",
"       <td rowspan=\"3\">",
"        Pre-exposure or postexposure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phone: 800-822-2463",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Website: file://www.vaccineplace.com/products/",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Purified chick embryo cell vaccine",
"       </td>",
"       <td rowspan=\"3\">",
"        RabAvert&reg;",
"       </td>",
"       <td>",
"        Novartis Vaccines and Diagnostics",
"       </td>",
"       <td rowspan=\"3\">",
"        1 mL",
"       </td>",
"       <td rowspan=\"3\">",
"        Intramuscular",
"       </td>",
"       <td rowspan=\"3\">",
"        Pre-exposure or postexposure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phone: 800-244-7668",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Website: file://www.rabavert.com",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"7\">",
"        Rabies immune globulin",
"       </td>",
"       <td rowspan=\"3\">",
"        Imogam&reg; Rabies-HT",
"       </td>",
"       <td>",
"        sanofi Pasteur",
"       </td>",
"       <td rowspan=\"3\">",
"        20 IU/kg",
"       </td>",
"       <td rowspan=\"3\">",
"        Local&bull;",
"       </td>",
"       <td rowspan=\"3\">",
"        Postexposure only",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phone: 800-822-2463",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Website: file://www.vaccineplace.com/products/",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        HyperRab&reg; S/D",
"       </td>",
"       <td>",
"        Talecris Biotherapeutics",
"       </td>",
"       <td rowspan=\"4\">",
"        20 IU/kg",
"       </td>",
"       <td rowspan=\"4\">",
"        Local&bull;",
"       </td>",
"       <td rowspan=\"4\">",
"        Posteexposure only",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bayer Biological Products",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phone: 800-243-4153",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Website: file://www.talecris-pi.info",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Imovax rabies I.D., administered intradermally, is no longer available in the United States.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      As much of the product as is anatomically feasible should be infiltrated into and around the wound. Any remaining product should be administered intramuscularly in the deltoid or quadriceps (at a location other than that used for vaccine inoculation to minimize potential interference).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Manning, SE, Rupprecht, CE, Fishbein, D, et al. Human rabies prevention-United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2008; 57:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_0_33804=[""].join("\n");
var outline_f33_0_33804=null;
var title_f33_0_33805="Immunohistochemical markers dx ATC";
var content_f33_0_33805=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F88072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F88072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Immunohistochemical markers useful for the diagnosis of anaplastic thyroid cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"40%\">",
"     </colgroup>",
"     <colgroup span=\"5\" width=\"12%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Immunohistochemical marker",
"       </td>",
"       <td class=\"subtitle1\">",
"        DTC",
"       </td>",
"       <td class=\"subtitle1\">",
"        MTC",
"       </td>",
"       <td class=\"subtitle1\">",
"        ATC",
"       </td>",
"       <td class=\"subtitle1\">",
"        SCC",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pankeratin (AE1/AE3)",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +/&minus;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &minus;*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High molecular weight keratins",
"       </td>",
"       <td class=\"centered\">",
"        + (PTC)",
"        <br/>",
"        &minus; (FTC)",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        &minus;/+",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TTF-1",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +/&minus;",
"       </td>",
"       <td class=\"centered\">",
"        &minus;/+",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PAX8",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +/&minus;",
"       </td>",
"       <td class=\"centered\">",
"        +/&minus;",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        +/&minus;",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thyroglobulin",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Synaptophysin",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chromogranin",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcitonin",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CEA",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        P53",
"       </td>",
"       <td class=\"centered\">",
"        &minus; (rare +)",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +/&minus;",
"       </td>",
"       <td class=\"centered\">",
"        +/&minus;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        E-cadherin",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B-catenin",
"       </td>",
"       <td class=\"centered\">",
"        Membranous",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        Nuclear or &minus;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        +/&minus; (nuclear)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD45",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ATC: anaplastic thyroid carcinoma; CD45: protein tyrosine phosphatase receptor type C; CEA: carcinoembryonic antigen; DTC: differentiated thyroid carcinoma; FTC: follicular thyroid carcinoma; MTC: medullary thyroid carcinoma; P53: cellular tumor antigen p53 or tumor protein p53; PAX8: paired box protein Pax 8 or paired box 8; PTC: papillary thyroid carcinoma; SCC: squamous cell carcinoma; TTF-1: thyroid transcription factor 1; +: positive; &minus;: negative; +/&minus;: usually positive, often negative; &minus;/+: usually negative, may be positive.",
"     <br/>",
"     * Plasmablastic lymphoma, anaplastic large cell lymphoma, and very rarely some diffuse large B cell lymphomas can express cytokeratin that is detected by AE1/AE3 cytokeratin monoclonal antibodies.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     PAX8 was detected by immunohistochemistry in normal B cells, but was not studied in lymphoma. It is very likely that various lymphomas express PAX8.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Smallridge RC, Ain KB, Asa SL, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 2012: 22:1104. Copyright &copy; 2012 Mary Ann Liebert, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_0_33805=[""].join("\n");
var outline_f33_0_33805=null;
var title_f33_0_33806="Use of the scoliometer";
var content_f33_0_33806=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Use of the scoliometer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 417px; height: 267px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The scoliometer is run along the patient's spine from caudad to cephalad while the patient is in the position assumed for the Adams forward bend test. In the above photograph, the right thoracic prominence causes the right side of the scoliometer to deviate upward and the ball to deviate to the left.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Susan Scherl.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_0_33806=[""].join("\n");
var outline_f33_0_33806=null;
var title_f33_0_33807="3D-ultrasound of complete cleft lip";
var content_f33_0_33807=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    3D-ultrasound of complete cleft lip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 330px; height: 350px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rendered 3-dimensional image of an early second trimester fetal face. The image demonstrates a unilateral complete cleft lip.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Shipp, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_0_33807=[""].join("\n");
var outline_f33_0_33807=null;
